

Señor Jefe

DIVISION DE NUEVAS CREACIONES

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

Bogotá, D.C.

SEFENILLO/RIA Y CLEPCIO
Radicación : 01029287 0000033 Folios: 109
Fecha (RAD): 2031-07-23 09:25:25
Tramite : CSE PATENTES D 1 REGISTRO/ 444 MUESTA
Dependencia: S.23 DIVISION DE NUEVAS CREACIONES

Re.: Expediente No. 01 29.287
Solicitud de patente
SMITHKLINE BEECHAM CORPORATION
Código 02 - 01 - 444

En relación con la solicitud contenida en el expediente de la referencia y, en particular, para dar respuesta a su último oficio proferido dentro del mismo, con el presente escrito acompaño:

1. Documento en que consta la cesión del derecho a la patente, otorgado por los inventores a favor de la sociedad solicitante, debidamente firmado, autenticado ante Notario Público y legalizado por Apostilla.
2. La dirección de mi representada, la sociedad Smithkline Beecham Corporation, se encuentra localizada en One Franklin Plaza y su domicilio ubicado en Filadelfia, Estado de Pennsylvania, Estados Unidos de América.

Acompaño un nuevo formato del petitorio en el que se ha incluido esta dirección.

3. Acompaño la copia certificada de la solicitud estadounidense 60/273,811 de 7 de Marzo de 2001, de la cual se reivindica prioridad, certificada su conformidad por la Administración que la recibió.
4. Acompaño el comprobante de pago de tasas por concepto de invocación de una de las prioridades, Recibo No. 44. 293/01--

El comprobante de pago de tasas por concepto de invocación de la otra prioridad se acompañó con la solicitud.

5. Acompaño copia del memorial radicado el día 5 de Junio de 2001 con el cual presenté la copia certificada de la solicitud estadounidense 60/198,493.
6. Acompaño el comprobante de pago de tasas por concepto de ciento noventa y cinco (195) palabras adicionales, a partir de la 150, en el extracto para publicación en la Gaceta, Recibo No. 44. 294/01

Le solicito se sirva agregar este escrito y sus anexos al expediente.

Renuncio al término faltante de traslado y le solicito se sirva continuar el trámite de la solicitud.

De Usted atentamente,

GERMAN CASTILLO GRAU
T.P. No. 2978 del C.S.J.



Industria y Comercio

SUPERINTENDENCIA

INDUSTRIA Y COMERCIO
Radicacion : 01029287 00000003 Folios: 109
Fecha (AMD): 2001-07-23 09:35:35
Tramite : 032 PATENTES D 1 REGISTRO/ 444 REPUESTA
Dependencia: 2020 DIVISION DE NUEVAS CREACIONES

NIT : 800176089-2

RECIBO OFICIAL DE CAJA : 01 - 44,293
FECHA : JULIO 19 DE 2001

***** CONSIGNACION *****

DEPOSITANTE	TIPO PAGO	BANCO	CUENTA	No. PAGO	FECHA PGB	Vr. PAGO
CASTILLO BRAU Y ASOCIADOS	CONSIGNACION	BANCO POPULAR	050-00110-6	3963929	19/07/2001	1,709,696.00

***** CONCEPTO *****

CANT. REENTISTICO	CONCEPTO	TOTAL CONCEPTO
50005-01-01 SOLICITUDES	82 INVOCACION DE UNA PRIORIDAD EN NU	100,000.00
	TOTAL :	\$ 100,000.00

SON: CIENTO MIL PESOS

RESPONSABLE :

RECIBO DE CAJA APLICADO AL EXPEDIENTE No.

Carrera 13 No. 27-00 Pisos 5, 7 y 10
Conmutador 382 0840
Fax 350 5220
E-mail: info@sic.gov.co
www.sic.gov.co
Bogotá, D.C., Colombia



Industria y Comercio
SUPERINTENDENCIA

143
SUPERINTENDENCIA Y COMERCIO Folios: 109
Radicación: 01029287 00000003
Fecha (APP): 2001-07-23 09:35:35
Trámite: 032 PATENTES D 1 REGISTRO/ 444 RESPUESTA
Dependencia: 2020 DIVISION DE NUEVAS CREACIONES

NIT: 800176089-2

RECIBO OFICIAL DE CAJA : 01 - 44,294
FECHA : JULIO 19 DE 2001

***** CONSIGNACION *****

DEPOSITANTE	TIPO PAGO	BANCO	CUENTA	No. PAGO	FECHA PGO	Vr. PAGO
CASTILLO GRAU Y ASOCIADOS	CONSIGNACION	BANCO POPULAR	050-00110-6	3963929	19/07/2001	1,709,696.00

***** CONCEPTO *****

CANT. RENTISTICO	CONCEPTO	TOTAL CONCEPTO
50005-01-01	SOLICITUDES	
	9 POR PALABRA ADICIONAL (A PARTIR D	105,300.00
	TOTAL :	\$ 105,300.00

SON: CIENTO CINCO MIL TRESCIENTOS PESOS

RESPONSABLE :

RECIBO DE CAJA APLICADO AL EXPEDIENTE No.

Carrera 13 No. 27-00 Pisos 5, 7 y 10
Conmutador 382 0840
Fax 350 5220
E-mail: info@sic.gov.co
www.sic.gov.co
Bogotá, D.C., Colombia

144
X50

APOSTILLE

(Convention de La Haye du 5 octobre 1961)

1. Country: United States of America
2. This public document has been signed by Carol E. Koennecker
3. acting in the capacity of Notary Public, Chester County
4. bears the seal/stamp Carol E. Koennecker, Notary Public, Commonwealth of Pennsylvania

Certified

5. at Harrisburg, Pennsylvania
6. The 24th day of May, 2001
7. by Kim Pizzigrilli, Secretary of the Commonwealth of Pennsylvania
8. No. 0112505
9. Seal/Stamp
10. Signature:



Kim Pizzigrilli

Kim Pizzigrilli

5

145

APOSTILLE

(Convention de La Haye du 5 octobre 1961)

1. Country: United States of America
2. This public document has been signed by Arlene E. Cannon
3. acting in the capacity of Notary Public, Montgomery County
4. bears the seal/stamp Arlene E. Cannon, Notary Public, Commonwealth of Pennsylvania

Certified

5. at Harrisburg, Pennsylvania
6. The 24th day of May, 2001
7. by Kim Pizzigrilli, Secretary of the Commonwealth of Pennsylvania
8. No. **0112506**
9. Seal/Stamp
10. Signature:



Kim Pizzigrilli

Kim Pizzigrilli


6

INVENTION ASSIGNMENT

The Undersigned, **Maxwell D. CUMMINGS** of 659 West Valley Road, Strafford, Pennsylvania 19087, a citizen of Canada; **Robert W. MARQUIS, Jr.** of 209 Country Gate, Wayne, Pennsylvania 19087, a citizen of United States of America; **Yu RU** of 1509 Hancock Lane, Wayne, Pennsylvania 19087, a citizen of Peoples Republic of China; **Scott K. THOMPSON** of 75 Guilford Circle, Phoenixville, Pennsylvania 19460, a citizen of United States of America; **Daniel F. VEBER** of 290 Batleson Road, Ambler, Pennsylvania 19002, a citizen of United States of America; and **Dennis S. YAMASHITA** of 531 Walker Road, Wayne, Pennsylvania 19087, a citizen of United States of America.

respectively, hereby appoints Dr. GERMAN CASTILLO GRAU, and/or Dr. ADRIANA CASTILLO GIBSON and/or Dr. LUIS FELIPE CASTILLO GIBSON, domiciled in Bogota, Colombia with offices at Carrera 13 No. 37043, 12th floor in Bogota, as attorney with ample and sufficient power, including that of receiving notifications and appointing judicial and extra-judicial attorneys, to apply for and obtain from the Colombian offices and authorities Patent of Invention for "PROTEASE INHIBITORS" to be issued in the name of SmithKline Beecham Corporation domiciled in Philadelphia, Pennsylvania United States of America to whom assignment has been made of all rights and titles on said invention/creation without any restriction whatsoever.

Signed at Exton, Pennsylvania



Maxwell D. CUMMINGS


Date: April 23, 2001

Commonwealth of Pennsylvania)
) ss.:
County of Chester)


Before me, a Notary Public, personally appeared Maxwell D. CUMMINGS known to me to be the person who executed the foregoing assignment and acknowledged it to be his/her act and deed.

Witness my hand and seal this 23 day of April, 2001.





Signed at King of Prussia, Pennsylvania



Robert W. MARQUIS, Jr.

Date:

04 May, 2001

152
147


Commonwealth of Pennsylvania)


) ss.:

County of Montgomery)


Before me, a Notary Public, personally appeared Robert W. MARQUIS, Jr. known to me to be the person who executed the foregoing assignment and acknowledged it to be his/her act and deed.

Witness my hand and seal this 4 day of May, 2001.





Signed at King of Prussia, Pennsylvania


Yu RU

Date:

01105/2001


Commonwealth of Pennsylvania)


) ss.:

County of Montgomery)

Before me, a Notary Public, personally appeared Yu RU. known to me to be the person who executed the foregoing assignment and acknowledged it to be his/her act and deed.

Witness my hand and seal this 1 day of May, 2001.





Signed at King of Prussia, Pennsylvania


Scott K. THOMPSON

Date:

15-May-2001

Commonwealth of Pennsylvania)


) ss.:

County of Montgomery)

Before me, a Notary Public, personally appeared Scott K. THOMPSON known to me to be the person who executed the foregoing assignment and acknowledged it to be his/her act and deed.

Witness my hand and seal this 15 day of May, 2001.





~~54~~
148

Date: May 21, 2001

Before me, a Notary Public, personally appeared Daniel F. VEBER known to me to be the person who executed the foregoing assignment and acknowledged it to be his/her act and deed.


May, 2001.
Arlene E. Connor



Date: 03-May-2001

Before me, a Notary Public, personally appeared Dennis S. Yamashita known to me to be the person who executed the foregoing assignment and acknowledged it to be his/her act and deed.

Witness my hand and seal this 3 day of May, 2001.





Espacio reservado para el sello de radicación

FORMULARIO UNICO DE SOLICITUD DE PATENTE
2000-3

1

SOLICITUD DE:

☒ X

Patente de Invención

☐

Patente de Modelo de Utilidad

2

SOLICITANTE

(71)

Nombre: SMITHKLINE BEECHAM CORPORATION

Dirección: One Franklin Plaza

Teléfono: Fax

E-mail

Domicilio: Filadelfia, Pennsylvania, E.U.A.

IDENTIFICACION

C.C. ☐ NIT ☐

C.E. ☐ Otro ☐

Número

3

REPRESENTANTE
APODERADO

(74)

Nombre: GERMAN CASTILLO GRAU

Dirección Carrera 13 No. 37-43, Piso 12

Teléfono: 2857480 Fax: 2858287

E-mail: info@castillograu.com

IDENTIFICACION

C.C. ☒ X NIT ☐

C.E. ☐ OTRO ☐

Número 17.017.671 TP 2.878

4

INVENTOR(ES)

(72)

Nombre: Ver lista adjunta

Dirección:

Teléfono: Fax

E-mail

Domicilio Ver lista adjunta

IDENTIFICACION

C.C. ☐ NIT ☐

C.E. ☐ OTRO ☐

Número

5

Título (54)

INHIBIDORES DE PROTEASA

6

Clasificación Internacional (51)

7

Prioridad

SI

☒ X

NO

☐

(33) País de Origen

E.U.A.

E.U.A.

(32) Fecha

Abr. 18, 2000

Mar. 7, 2001

(31) Número de Solicitud

60/198.483

60/273.811

8

Para publicar a partir de la fecha de la presente solicitud a los:

6 meses

☐

12 meses

☐

18 meses

☐

Otro

☐

9

Comprobante de pago N°:

01-44-293/p1-44-294/p1-


Fecha:

Instrucciones para el diligenciamiento del presente formulario, ver reverso de esta página.

155
149

10

150 \$



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE


United States Patent and Trademark Office

June 28, 2001

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 60/273,811

FILING DATE: March 07, 2001



**By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS**

M. Lee

**M. LEE
Certifying Officer**

11

03-08-01

A/Prov

151

EXPRESS MAIL CERTIFICATE

Express Mail® Mailing Label Number EL421194886US

Date Of Deposit: 7 March 2001

I Herby Certify That This Paper Or Fee Is Being Deposited With The United States Postal Service "Express Mail Post Office To Addressee" Service Under 37 CFR 1.18 On The Date Indicated Above And Is Addressed To: Assistant Commissioner Of Patents, Washington, D.C. 20231.

Name Of Person Mailing Paper Or Fee

(Type Or Print)

Signature

PROVISIONAL APPLICATION COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION for PATENT under 37 CFR 1.53(c).

Docket No.

P51127P1

INVENTOR(s) / APPLICANT(s)

Last Name	First Name	Middle Initial	Residence (City and Either State or Foreign Country)
Marquis, Jr.	Robert	W.	St. Davids, Pennsylvania
Veber	Daniel	F.	Ambler, Pennsylvania
Ru	Yu		Havertown, Pennsylvania
Cummings	Maxwell	D.	Strafford, Pennsylvania
Thompson, Jr.	Scott	K.	Phoenixville, Pennsylvania
Yamashita	Dennis	S.	King of Prussia, Pennsylvania

TITLE OF THE INVENTION (280 characters max)

PROTEASE INHIBITORS

CORRESPONDENCE ADDRESS

SMITHKLINE BEECHAM CORPORATION

Corporate Intellectual Property - UW2220

709 Swedeland Road

King of Prussia

Telephone No. 610-270-5018

Facsimile No. 610-270-5090

State

PA

Zip Code

19406-2799

Country

United States of America

ENCLOSED APPLICATION PARTS (check all that apply)

☒ Specification

Number of Pages

94

☐ Small Entity Statement☐ Drawings

Number of Sheets

☒ Other (specify) Abstract (1 page)

METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT

☒ The Commissioner is hereby authorized to charge filing fees and credit Deposit Account No. 19-2570PROVISIONAL FILING
FEE AMOUNT (\$)

\$150.00

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

☒ No.☐ Yes, the name of the U.S. Government agency and the Government contract number are: _____Respectfully submitted,
Signature:

Yunq B. Stercho, Ph.D.

Date:

March 7, 2001

Registration No.:

33,797

☐ Additional inventors are being named on separately numbered sheets attached hereto.

PROVISIONAL APPLICATION FILING ONLY

SEND TO: Assistant Commissioner for Patents, Box Provisional Application, Washington, D.C. 20231.

a:\types\app\p51127p-1\provis.doc



20462

PATENT TRADEMARK OFFICE

12

PROTEASE INHIBITORS**FIELD OF THE INVENTION**

This invention relates in general to the use of 4-amino-azepan-3-one protease inhibitors, particularly such inhibitors of cathepsin S, in the treatment of diseases in which cathepsin S is implicated, especially treatment or prevention of autoimmune disease; treatment or prevention of a disease state caused by the formation of atherosclerotic lesions and complications arising therefrom; and diseases requiring inhibition, for therapy, of a class II MHC-restricted immune response, inhibition of an arthritic response, inhibition of an allergic response, inhibition of immune response against a transplanted organ or tissue, or inhibition of elastase activity in atheroma; and novel compounds for use therewith.

BACKGROUND OF THE INVENTION

Cathepsins are a family of enzymes which are part of the papain superfamily of cysteine proteases. Cathepsins K, B, H, L, N and S have been described in the literature.

Cathepsins function in the normal physiological process of protein degradation in animals, including humans, e.g., in the degradation of connective tissue. However, elevated levels of these enzymes in the body can result in pathological conditions leading to disease. Thus, cathepsins have been implicated as causative agents in various disease states, including but not limited to, infections by *pneumocystis carinii*, *trypanosoma cruzi*, *trypanosoma brucei brucei*, and *Crithidia fusiculata*; as well as in schistosomiasis, malaria, tumor metastasis, metachromatic leukodystrophy, muscular dystrophy, amyotrophy, and the like. See International Publication Number WO 94/04172, published on March 3, 1994, and references cited therein. See also European Patent Application EP 0 603 873 A1, and references cited therein. Two bacterial cysteine proteases from *P. gingivallis*, called gingipains, have been implicated in the pathogenesis of gingivitis. Potempa, J., et al. (1994) *Perspectives in Drug Discovery and Design*, 2, 445-458. Cathepsin K is believed to play a causative role in diseases of excessive bone or cartilage loss. See International Publication Number WO 97/16433, published on May 9, 1997, and references cited therein.

Pathological levels of cathepsin S have been implicated in a variety of disease states. For instance, mice treated with inhibitor exhibited attenuated antibody response indicating that selective inhibition of cathepsin S may provide a therapeutic strategy for asthma and autoimmune disease processes. Riese, Richard J., et al., *J. Clin. Invest.* 1998 101(11), 2351-2363. Thus, selective inhibition of cathepsin S may provide an effective treatment for diseases requiring, for therapy or prevention: inhibition of a class II MHC-

- restricted immune response; treatment and/or prevention of an autoimmune disease state such as rheumatoid arthritis, multiple sclerosis, juvenile-onset diabetes, systemic lupus erythematosus, discoid lupus erythematosus, pemphigus vulgaris, pemphigoid, Grave's disease, myasthenia gravis, Hashimoto's thyroiditis, scleroderma, dermatomyositis,
- 5 Addison's disease, pernicious anemia, primary myxoedema, thyrotoxicosis, autoimmune atrophic gastritis, stiff-man syndrome, Goodpasture's syndrome, sympathetic ophthalmia, phacogenic uveitis, autoimmune haemolytic anaemia, idiopathic thrombocytopenic purpura, idiopathic leucopenia, primary biliary cirrhosis, active chronic hepatitis, cryptogenic cirrhosis, ulcerative colitis, Sjogren's syndrome, and mixed connective tissue disease;
- 10 inhibition of an asthmatic response; inhibition of an allergic response; inhibition of immune response against transplanted organ or tissue (see I. Roitt, J. Brostoff, D. Male, *Immunology*, Fifth Edition, 1998, p.368; R. J. Riese, et al *Immunity*, 1996, 4, 357-366; GP Shi, et al *Immunity* 1999, 10, 197-206; T. Nakagawa, et al *Immunity* 1999, 10, 207-217; and International Publication No. WO 97/40066); inhibition of elastase activity in atheroma;
- 15 and treatment or prevention of a disease state caused by the formation of atherosclerotic lesions or complications arising therefrom (G. K. Sukhova, et al *J. Clin. Invest.* 1998, 102, 576).

- Several classes of cysteine protease inhibitors are known. Palmer et. al. (1995) *J. Med. Chem.*, 38, 3193, disclose certain vinyl sulfones which irreversibly inhibit cysteine proteases, such as the cathepsins B, L, S, O2 and cruzain. Other classes of compounds, such
- 20 as aldehydes, nitriles, α -ketocarbonyl compounds, halomethyl ketones, diazomethyl ketones, (acyloxy)methyl ketones, ketomethylsulfonium salts and epoxy succinyl compounds have also been reported to inhibit cysteine proteases. See Palmer, *id.* and references cited therein.
- 25 U.S. Patent No. 4,518,528 discloses peptidyl fluoromethyl ketones as irreversible inhibitors of cysteine protease. Published International Patent Application No. WO 94/04172, and European Patent Application Nos. EP 0 525 420 A1, EP 0 603 873 A1, and EP 0 611 756 A2 describe alkoxymethyl and mercaptomethyl ketones which inhibit the cysteine proteases cathepsins B, H and L. International Patent Application No.
- 30 PCT/US94/08868 and European Patent Application No. EP 0 623 592 A1 describe alkoxymethyl and mercaptomethyl ketones which inhibit the cysteine protease II-1 β convertase. Alkoxymethyl and mercaptomethyl ketones have also been described as inhibitors of the serine protease kininogenase (International Patent Application No. PCT/GB91/01479).

154

Aza-peptides which are designed to deliver the azamino acid to the active site of serine proteases, and which possess a good leaving group, are disclosed by Elmore *et al.*, *Biochem. J.*, 1968, 107, 103, Gariker *et al.*, *Biochem. J.*, 1974, 139, 555, Gray *et al.*, *Tetrahedron*, 1977, 33, 837, Gupton *et al.*, *J. Biol. Chem.*, 1984, 259, 4279, Powers *et al.*, *J. Biol. Chem.*, 1984, 259, 4288, and are known to inhibit serine proteases. In addition, *J. Med. Chem.*, 1992, 35, 4279, discloses certain aza-peptide esters as cysteine protease inhibitors.

Antipain and leupeptin are described as reversible inhibitors of cysteine protease in McConnell *et al.*, *J. Med. Chem.*, 33, 86; and also have been disclosed as inhibitors of serine protease in Umezawa *et al.*, 45 *Mesh. Enzymol.* 678. E64 and its synthetic analogs are also well-known cysteine protease inhibitors (Barrett, *Biochem. J.*, 201, 189, and Grinde, *Biochem. Biophys. Acta*, 701, 328).

1,3-diamido-propanones have been described as analgesic agents in U.S. Patent Nos. 4,749,792 and 4,638,010.

A variety of cysteine and serine protease inhibitors, especially of cathepsin K, have been disclosed in International Publication Number WO 97/16433, published on May 9, 1997.

We have now discovered that certain 4-amino-azepan-3-one compounds inhibit cathepsin S, and are useful in the treatment of diseases in which cathepsin S is implicated.

SUMMARY OF THE INVENTION

An object of the present invention is to provide methods of treatment which use 4-amino-azepan-3-one carbonyl protease inhibitors of cathepsin S of Formula I and which are useful for treating diseases which may be therapeutically modified by altering the activity of cathepsin S.

In a particular aspect, the methods of this invention are especially useful for treatment or prevention of autoimmune disease; treatment or prevention of a disease state caused by the formation of atherosclerotic lesions and complications arising therefrom; and diseases requiring inhibition, for therapy, of a class II MHC-restricted immune response, inhibition of an asthmatic response, inhibition of an allergic response, inhibition of immune response against a transplanted organ or tissue, or inhibition of elastase activity in atheroma.


Another object of the present invention is to provide novel compounds for use in the present methods.

15

50273811.030701

DETAILED DESCRIPTION OF THE INVENTION


The present invention provides a method of inhibiting cathepsin S comprising administering to an animal, particularly a mammal, most particularly a human being in need thereof, an effective amount of a compound of Formula I:





I

wherein:

R¹ is selected from the group consisting of:



R^2 is selected from the group consisting of: H, C_1 -alkyl, C_3 -cycloalkyl- C_0 -alkyl, Ar- C_0 -alkyl, Het- C_0 -alkyl, $R^9C(O)-$, $R^9C(S)-$, R^9SO_2- , $R^9OC(O)-$,



R³ is selected from the group consisting of: H, C₁₋₆-alkyl, C₃₋₆-cycloalkyl-C₀-alkyl, C₂₋₆-alkenyl, C₂₋₆-alkynyl, HetC₀₋₆-alkyl, ArC₀₋₆-alkyl, Ar-ArC₀₋₆-alkyl, Ar-HetC₀₋₆-alkyl, Het-ArC₀₋₆-alkyl, and Het-HetC₀₋₆-alkyl;

R³ and R' may be connected to form a pyrrolidine, piperidine or morpholine ring.

R⁴ is selected from the group consisting of: H, C₁₋₆alkyl, C₃₋₆cycloalkyl-C₀₋₆alkyl, Ar-C₀₋₆alkyl, Het-C₀₋₆alkyl, R⁵C(O)-, R⁵C(S)-, R⁵SO₂-, R⁵OC(O)-, R⁵R¹³NC(O)-, and R⁵R¹³NC(S)-;

R^5 is selected from the group consisting of: H, C_1 -alkyl, C_2 -alkenyl, C_2 -alkynyl, C_3 -cycloalkyl- C_0 -alkyl, Ar- C_0 -alkyl and Het- C_0 -alkyl;

R^6 is selected from the group consisting of: H, C_1 -alkyl, C_3 -cycloalkyl- C_0 -alkyl, Ar- C_0 -alkyl, and Het- C_0 -alkyl;

5 R^7 is selected from the group consisting of: H, C_1 -alkyl, C_3 -cycloalkyl- C_0 -alkyl, Ar- C_0 -alkyl, Het- C_0 -alkyl, $R^{10}C(O)-$, $R^{10}C(S)-$, $R^{10}SO_2-$, $R^{10}OC(O)-$, $R^{10}R^{14}NC(O)-$, and $R^{10}R^{14}NC(S)-$;

R^8 is selected from the group consisting of: H, C_1 -alkyl, C_2 -alkenyl, C_2 -alkynyl, Het- C_0 -alkyl and Ar- C_0 -alkyl;

10 R^9 is selected from the group consisting of: C_1 -alkyl, C_3 -cycloalkyl- C_0 -alkyl, Ar- C_0 -alkyl and Het- C_0 -alkyl;

R^{10} is selected from the group consisting of: C_1 -alkyl, C_3 -cycloalkyl- C_0 -alkyl, Ar- C_0 -alkyl and Het- C_0 -alkyl;

15 R^{11} is selected from the group consisting of: H, C_1 -alkyl, Ar- C_0 -alkyl, and Het- C_0 -alkyl;

R^{12} is selected from the group consisting of: H, C_1 -alkyl, Ar- C_0 -alkyl, and Het- C_0 -alkyl;

R^{13} is selected from the group consisting of: H, C_1 -alkyl, Ar- C_0 -alkyl, and Het- C_0 -alkyl;

20 R^{14} is selected from the group consisting of: H, C_1 -alkyl, Ar- C_0 -alkyl, and Het- C_0 -alkyl;

R' is selected from the group consisting of: H, C_1 -alkyl, Ar- C_0 -alkyl, and Het- C_0 -alkyl;


25 R'' is selected from the group consisting of: H, C_1 -alkyl, Ar- C_0 -alkyl, or Het- C_0 -alkyl;

R''' is selected from the group consisting of: H, C_1 -alkyl, C_3 -cycloalkyl- C_0 -alkyl, Ar- C_0 -alkyl, and Het- C_0 -alkyl;

X is selected from the group consisting of: CH_2 , S, and O;

Z is selected from the group consisting of: $C(O)$ and CH_2 ;

30 and pharmaceutically acceptable salts, hydrates and solvates thereof.



In compounds of Formula I, R^1 is preferably compounds:

. In such

157

R³ is selected from the group consisting of: H, C₁-alkyl, C₃-cycloalkyl-C₀-alkyl, C₂-alkenyl, C₂-alkynyl, Het-C₀-alkyl and Ar-C₀-alkyl, preferably C₃-cycloalkyl-C₀-alkyl and C₁-alkyl, especially selected from the group consisting of: cyclohexylmethyl and 2,2-dimethyl propyl, more preferably C₃-cycloalkyl-C₀-alkyl, most preferably cyclohexylmethyl;

R⁴ is selected from the group consisting of: H, C₁-alkyl, C₃-cycloalkyl-C₀-alkyl, Ar-C₀-alkyl, Het-C₀-alkyl, R⁵C(O)-, R⁵C(S)-, R⁵SO₂-, R⁵OC(O)-, R⁵R¹³NC(O)-, and R⁵R¹³NC(S)-, preferably R⁵C(O)-.

R⁵ is selected from the group consisting of: C₁-alkyl, C₂-alkenyl, C₂-alkynyl, C₃-cycloalkyl-C₀-alkyl, Ar-C₀-alkyl or Het-C₀-alkyl. Preferably R⁵ is selected from the group consisting of: C₁-alkyl, C₃-cycloalkyl-C₀-alkyl, Ar-C₀-alkyl and Het-C₀-alkyl. More preferably R⁵ is selected from the group consisting of:

furanyl, especially furan-2-yl and furan-3-yl, more especially aryl substituted furanyl, even more especially 5-(4-chloro-phenyl)-furan-2-yl and 5-(3-trifluoromethyl-phenyl)-furan-2-yl;

benzofuranyl, especially benzofuran-2-yl, more especially C₁-alkoxy substituted benzofuranyl, particularly 5,6-dimethoxy-benzofuran-2-yl and 5-(2-morpholin-4-ylethoxy)benzofuran-2-yl;

thiophenyl, especially thiophene-3-yl and thiophene-2-yl, more especially Het-C₀-alkyl-thiophenyl; particularly 5-pyridin-2-yl-thiophene-2-yl, more especially C₁-alkyl-thiophenyl, particularly 5-methyl-thiophene-2-yl and 3-methyl-thiophene-2-yl; more especially C₁-alkoxy -thiophenyl, particularly 3-ethoxy-thiophene-2-yl;

furo[3,2-b]-pyridine-2-yl, especially C₁-alkyl-furo[3,2-b]-pyridine-2-yl, more especially 3-methyl-furo[3,2-b]-pyridine-2-yl;

thiazolyl, especially thiazole-5-yl, more especially Het-C₀-alkyl-thiazolyl, particularly 4-methyl-2-pyridin-2-yl-thiazole-5-yl;

phenyl, especially halogen substituted phenyl, particularly bromophenyl, more particularly 4-bromophenyl;

cyclobutyl;

cyclopentyl;

tetrahydrofuranyl, tetrahydrofuran-2-yl;

selenophenyl, especially selenophene-2-yl; and


thieno[3,2-b]thiophenyl, especially thieno[3,2-b]thiophene-2-yl.

R' is selected from the group consisting of: H, C₁-alkyl, Ar-C₀-alkyl, and Het-C₀-alkyl, preferably H.

R

19

60273811.030701



R^2 is R^9SO_2 ;

R^3 is cyclohexylmethyl;

R^4 is $R^5C(O)$;

5 R^5 is selected from the group consisting of: furanyl, especially furan-2-yl, and thiophenyl, especially thiophene-3-yl;

R^9 is selected from the group consisting of: pyridin-2-yl and 1-oxy-pyridin-2-yl, preferably pyridin-2-yl;

R' is H

10 R'' is H; and

R''' is selected from the group consisting of: H and C_{1-6} alkyl. When R''' is C_{1-6} alkyl, R''' is:


especially selected from the group consisting of: methyl, ethyl, propyl, butyl, pentyl and hexyl, more especially methyl;

15 preferably selected from the group consisting of: 5-, 6- or 7- C_{1-6} alkyl, especially selected from the group consisting of: 5-, 6- or 7-methyl, -ethyl, -propyl, -butyl, -pentyl and -hexyl, more especially selected from the group consisting of: 5-, 6- or 7-methyl;

more preferably selected from the group consisting of: 6- or 7- C_{1-6} alkyl, especially selected from the group consisting of: 6- or 7-methyl, -ethyl, -propyl, -butyl, -pentyl and -

20 hexyl, more especially selected from the group consisting of: 6- or 7-methyl;

yet more preferably *cis*-7- C_{1-6} alkyl as shown in Formula Ia:




Ia


25 wherein R''' is C_{1-6} alkyl, especially selected from the group consisting of: methyl, ethyl, propyl, butyl, pentyl and hexyl;

most preferably *cis*-7- methyl, as shown in Formula Ia wherein R''' is methyl.


Compounds of Formula I selected from the following group are particularly preferred for use in the present invention:




- 5 benzofuran-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




- 10 5-(3-trifluoromethyl-phenyl)-furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




- 15 5-(4-chloro-phenyl)-furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




- 5-(4-chloro-phenyl)-furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




- 20 5-(3-trifluoromethyl-phenyl)-furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




5,6-dimethoxy-benzofuran-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




5 furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;



10 benzofuran-2-carboxylic acid ((S)-2-cyclohexyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




15 thiophene-3-carboxylic acid ((S)-2-cyclohexyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




3-methyl-furo[3,2-b]-pyridine-2-carboxylic acid ((S)-2-cyclohexyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;

5




5-(2-morpholin-4-yl-ethoxy)-benzofuran-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




10

4-methyl-2-pyridin-2-yl-thiazole-5-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




15

5-pyridin-2-yl-thiophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




5

thiophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;



10


thiophene-3-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;



15


5-methyl-thiophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;

170
164




3-methyl-thiophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;

5




3-ethoxy-thiophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;



10

4-bromo-N-((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-benzamide;




15 cyclobutanecarboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;


25

60273811-030701

165




cyclopentanecarboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




5

(S)-tetrahydro-furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




10

(R)-tetrahydro-furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;



15

furan-3-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




5-pyridin-2-yl-thiophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;


20

26

60273 11-030701


X
166

4-methyl-2-pyridin-2-yl-thiazole-5-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




5

5-(2-morpholin-4-yl-ethoxy)-benzofurani-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;



10

furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




15

furan-3-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;


27

60273811-030701


167




thiophene-3-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




5 thiophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;



10 5-methyl-thiophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




15 3-methyl-thiophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




20 3-ethoxy-thiophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;


28




selenophene-2-carboxylic acid [(S)-2-cyclohexyl-1-[(R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)azepan-4-ylcarbonyl]-ethyl]-amide;



furan-2-carboxylic acid [(S)-2-cyclohexyl-1-[(4S,7R)-7-methyl-3-oxo-1-propylazepan-4-ylcarbonyl]-ethyl]-amide;




thiophene-3-carboxylic acid [(S)-2-cyclohexyl-1-[(4S,7R)-7-methyl-3-oxo-1-propylazepan-4-ylcarbonyl]-ethyl]-amide;




benzofuran-2-carboxylic acid [(S)-2-cyclohexyl-1-[(4S,7R)-7-methyl-3-oxo-1-propylazepan-4-ylcarbonyl]-ethyl]-amide;

169 ¹⁵




2,2,4-trideutero-Furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;

5




thiophene-3-carboxylic acid ((S)-3,3-dimethyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl)-amide;

10



furan-2-carboxylic acid ((S)-3,3-dimethyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl)-amide; and

15



thieno[3,2-b] thiophene-2-carboxylic acid ((S)-3,3-dimethyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl)-amide.


20

Compounds of Formula I selected from the following group are more particularly preferred for use in the present invention:


30

60273811-030701

170 3/4




furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide; and




thiophene-3-carboxylic acid ((S)-2-cyclohexyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide.

The following compound of Formula I is the most preferred for use in the present invention:



furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide.

The present invention provides the following novel compounds:




3/


FOA080-TT8E4209

171


5-(2-morpholin-4-yl-ethoxy)-benzofuran-2-carboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide;




5 4-methyl-2-pyridin-2-yl-thiazole-5-carboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide;




10 5-pyridin-2-yl-thiophene-2-carboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide;



15 furan-2-carboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide;




20 thiophene-2-carboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide;



32

60273811.030701


thiophene-3-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbonyl]-ethyl)-amide;




5

5-methyl-thiophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbonyl]-ethyl)-amide;

10




3-methyl-thiophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbonyl]-ethyl)-amide;




15

3-ethoxy-thiophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbonyl]-ethyl)-amide;




4-bromo-N-((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbonyl]-ethyl)-benzamide;

20




cyclobutanecarboxylic acid ((S)-2-cyclohexyl-4-((S)-2-cyclohexyl-1-((pyridin-2-yl)sulfonyl)azepan-4-ylcarbamoyl]-ethyl)-amide;

5




cyclopentanecarboxylic acid ((S)-2-cyclohexyl-4-((S)-2-cyclohexyl-1-((pyridine-2-yl)sulfonyl)azepan-4-ylcarbamoyl]-ethyl)-amide;




10

(S)-tetrahydro-furan-2-carboxylic acid ((S)-2-cyclohexyl-4-((S)-2-cyclohexyl-1-((pyridine-2-yl)sulfonyl)azepan-4-ylcarbamoyl]-ethyl)-amide;




15

(R)-tetrahydro-furan-2-carboxylic acid ((S)-2-cyclohexyl-4-((S)-2-cyclohexyl-1-((pyridine-2-yl)sulfonyl)azepan-4-ylcarbamoyl]-ethyl)-amide;




20

furan-3-carboxylic acid ((S)-2-cyclohexyl-4-((S)-2-cyclohexyl-1-((pyridine-2-yl)sulfonyl)azepan-4-ylcarbamoyl]-ethyl)-amide;




5-pyridin-2-yl-thiophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxo-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




5

4-methyl-2-pyridin-2-yl-thiazole-5-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxo-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




10

5-(2-morpholin-4-yl-ethoxy)-benzofuran-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxo-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




15

furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxo-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




175


furan-3-carboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide;




5 thiophene-3-carboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide;




10 thiophene-2-carboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide;



15 5-methyl-thiophene-2-carboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide;



20 3-methyl-thiophene-2-carboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide;




3-ethoxy-thiophene-2-carboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide;

36


50273811.03 701

176



selenophene-2-carboxylic acid {(S)-2-cyclohexyl-1-[(R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide; and

5



2,2,4-trideutero-Furan-2-carboxylic acid {(S)-2-cyclohexyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide.

10

Specific representative compounds used in the present invention are set forth in Examples 1-44.

Compared to the corresponding 5 and 6 membered ring compounds, the 7 membered ring compounds used in the present invention are configurationally more stable at the carbon center alpha to the ketone.

The present invention also uses deuterated analogs of the inventive compounds. Representative examples of such deuterated compounds are set forth in Examples 7 and 41. A representative synthetic route for the deuterated compounds of the present invention are set forth in Scheme 3 and Examples 7 and 41, below. The deuterated compounds used in the present invention exhibit superior chiral stability compared to the protonated isomer.

Definitions

The compounds used in the present invention include all hydrates, solvates, complexes and prodrugs. Prodrugs are any covalently bonded compounds which release the active parent drug according to Formula I *in vivo*. If a chiral center or another form of an isomeric center is present in a compound used in the present invention, all forms of such isomer or isomers, including enantiomers and diastereomers, are intended to be covered herein. Compounds used in the present methods containing a chiral center may be used as a

37

60273811-030701

182
177

racemic mixture, an enantiomerically enriched mixture, or the racemic mixture may be separated using well-known techniques and an individual enantiomer may be used alone. In cases in which compounds have unsaturated carbon-carbon double bonds, both the *cis* (Z) and *trans* (E) isomers are within the scope of this invention. In cases wherein compounds may exist in tautomeric forms, such as keto-enol tautomers, each tautomeric form is contemplated as being included within this invention whether existing in equilibrium or predominantly in one form.

The meaning of any substituent at any one occurrence in Formula I or any subformula thereof is independent of its meaning, or any other substituent's meaning, at any other occurrence, unless specified otherwise.

Abbreviations and symbols commonly used in the peptide and chemical arts are used herein to describe the compounds of the present invention. In general, the amino acid abbreviations follow the IUPAC-IUB Joint Commission on Biochemical Nomenclature as described in *Eur. J. Biochem.*, 158, 9 (1984).

"Proteases" are enzymes that catalyze the cleavage of amide bonds of peptides and proteins by nucleophilic substitution at the amide bond, ultimately resulting in hydrolysis. Such proteases include: cysteine proteases, serine proteases, aspartic proteases, and metalloproteases. The compounds of the present invention are capable of binding more strongly to the enzyme than the substrate and in general are not subject to cleavage after enzyme catalyzed attack by the nucleophile. They therefore competitively prevent proteases from recognizing and hydrolyzing natural substrates and thereby act as inhibitors.

The term "amino acid" as used herein refers to the D- or L- isomers of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine.

"Hydrogen" or "H" includes all of its possible isotopes, including "deuterium" or "D" or ^2H ; and "tritium" or "T" or ^3H .

"C₁₋₆alkyl" as applied herein is meant to include substituted and unsubstituted methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and t-butyl, pentyl, n-pentyl, isopentyl, neopentyl and hexyl and the simple aliphatic isomers thereof. C₁₋₆alkyl may be optionally substituted by a moiety selected from the group consisting of: OR¹², C(O)R¹², SR¹², S(O)R¹², NR¹², R¹²NC(O)OR⁵, CO₂R¹², CO₂NR¹², N(C=NH)NH₂, Het, C₃₋₆cycloalkyl, and Ar, where R⁵ is selected from the group consisting of: H, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl-C₀₋₆alkyl, Ar-C₀₋₆alkyl and Het-C₀₋₆alkyl; and R¹² is selected from the group consisting of: H, C₁₋₆alkyl, Ar-C₀₋₆alkyl, and Het-C₀₋₆alkyl;

38

60273811-030701

178

"C₃₋₆cycloalkyl" as applied herein is meant to include substituted and unsubstituted cyclopropane, cyclobutane, cyclopentane and cyclohexane.

"C₂₋₆alkenyl" as applied herein means an alkyl group of 2 to 6 carbons wherein a carbon-carbon single bond is replaced by a carbon-carbon double bond. C₂₋₆alkenyl includes ethylene, 1-propene, 2-propene, 1-butene, 2-butene, isobutene and the several isomeric pentenes and hexenes. Both cis and trans isomers are included.

"C₂₋₆alkynyl" means an alkyl group of 2 to 6 carbons wherein one carbon-carbon single bond is replaced by a carbon-carbon triple bond. C₂₋₆alkynyl includes acetylene, 1-propyne, 2-propyne, 1-butyne, 2-butyne, 3-butyne and the simple isomers of pentyne and hexyne.

"Halogen" means F, Cl, Br, and I.

"Ar" or "aryl" means phenyl or naphthyl, optionally substituted by one or more of Ph-C₀₋₆alkyl; Het-C₀₋₆alkyl; C₁₋₆alkoxy; Ph-C₀₋₆alkoxy; Het-C₀₋₆alkoxy; OH, (CH₂)₁₋₆NR¹⁵R¹⁶; O(CH₂)₁₋₆NR¹⁵R¹⁶; C₁₋₆alkyl, OR¹⁷, N(R¹⁷)₂, SR¹⁷, CF₃, NO₂, CN, CO₂R¹⁷, CON(R¹⁷), F, Cl, Br or I; where R¹⁵ and R¹⁶ are H, C₁₋₆alkyl, Ph-C₀₋₆alkyl, naphthyl-C₀₋₆alkyl or Het-C₀₋₆alkyl; and R¹⁷ is phenyl, naphthyl, or C₁₋₆alkyl.

As used herein "Het" or "heterocyclic" represents a stable 5- to 7-membered monocyclic, a stable 7- to 10-membered bicyclic, or a stable 11- to 18-membered tricyclic heterocyclic ring which is either saturated or unsaturated, and which consists of carbon atoms and from one to three heteroatoms selected from the group consisting of N, O and S, and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure, and may optionally be substituted with one or two moieties selected from C₀₋₆Ar, C₁₋₆alkyl, OR¹⁷, N(R¹⁷)₂, SR¹⁷, CF₃, NO₂, CN, CO₂R¹⁷, CON(R¹⁷), F, Cl, Br and I, where R¹⁷ is phenyl, naphthyl, or C₁₋₆alkyl. Examples of such heterocycles include piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl, pyridinyl, 1-oxo-pyridinyl, pyrazinyl, oxazolidinyl, oxazoliny, oxazolyl, isoxazolyl, morpholinyl, thiazolidinyl, thiazoliny, thiazolyl, quinuclidinyl, indolyl, quinolinyl, quinoxalinyl, isoquinolinyl, benzimidazolyl, benzopyranyl, benzoxazolyl, furanyl, benzofuranyl, thiophenyl, benzo[b]thiophenyl, thieno[3,2-b]thiophenyl, benzo[1,3]dioxolyl, 1,8 naphthyridinyl, pyranyl, tetrahydrofuranyl, tetrahydropyranyl, thienyl, benzoxazolyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, and oxadiazolyl, as well as triazolyl, thiadiazolyl, oxadiazolyl, isothiazolyl,

79

50273811.030701

X
179

imidazolyl, pyridazinyl, pyrimidinyl, triazinyl and tetrazinyl which are available by routine chemical synthesis and are stable. The term heteroatom as applied herein refers to oxygen, nitrogen and sulfur.

Here and throughout this application the term C₀ denotes the absence of the substituent group immediately following; for instance, in the moiety ArC₀-alkyl, when C is 0, the substituent is Ar, e.g., phenyl. Conversely, when the moiety ArC₀-alkyl is identified as a specific aromatic group, e.g., phenyl, it is understood that the value of C is 0.

Certain radical groups are abbreviated herein. t-Bu refers to the tertiary butyl radical, Boc refers to the t-butyloxycarbonyl radical, Fmoc refers to the fluorenylmethoxycarbonyl radical, Ph refers to the phenyl radical, Cbz refers to the benzyloxycarbonyl radical.

Certain reagents are abbreviated herein. m-CPBA refers to 3-chloroperoxybenzoic acid, EDC refers to N-ethyl-N-(dimethylaminopropyl)-carbodiimide, P-EDC refers to polymer supported EDC, DMF refers to dimethyl formamide, DMSO refers to dimethyl sulfoxide, NMM is N-methylmorpholine, TEA refers to triethylamine, TFA refers to trifluoroacetic acid, and THF refers to tetrahydrofuran.

Methods of Preparation

Compounds of the general formula I may be prepared in a fashion analogous to that outlined in Schemes 1 to 5. Alkylation of benzyl-N-allylcarbamate (1) with a base such as sodium hydride and 5-bromo-1-pentene provides the diene 2 (Scheme 1). Treatment of 2 with bis(tricyclohexylphosphine)benzylidene ruthenium (IV) dichloride olefin metathesis catalysts developed by Grubbs provides the tetrahydroazepine 3. Epoxidation of 3 with oxidizing agents common to the art such as m-CPBA provides the epoxide 4. Nucleophilic epoxide ring opening may be effected with a reagent such as sodium azide to provide the azido alcohol 5 which may be reduced to the amino alcohol 6 under conditions common to the art such as 1,3-propanedithiol and triethylamine in methanol or triphenylphosphine in THF and water. The amine of compound 6 may be protected with di-tert-butylidicarbonate to provide the N-Boc derivative 7 (Scheme 2). Removal of the benzyloxycarbonyl protecting group may be effected by treatment of 7 with hydrogen gas in the presence of a catalyst such as 10% Pd/C to provide the amine 8. Treatment of amine 8 with a sulfonyl chloride such as 2-pyridinesulfonyl chloride in the presence of a base such as N-methylmorpholine or triethylamine provides the sulfonamide derivative 9. Removal of the tert-butoxycarbonyl protecting group may be effected with an acid such as hydrochloric acid to provide intermediate 10. Coupling of 10 with an acid such as N-Boc-phenylalanine

40


.50273811.030701

186
180

in the presence of a coupling agent common to the art such as HBTU or polymer supported EDC provides the alcohol intermediate 11. Removal of the *tert*-butoxycarbonyl protecting group under acidic conditions provides amine 12. Coupling of 12 with an acid such as benzofuran-2-carboxylic acid in the presence of a coupling agent such as HBTU or polymer supported EDC provides alcohol 13. Alcohol 13 may be oxidized with an oxidant common to the art such as pyridine sulfur trioxide complex in DMSO and triethylamine or the Dess-Martin periodinane to provide the ketone 14.

Scheme 1

10




Reagents and conditions: (a) NaH, 5-bromo-1-pentene, NaH; (b) bis(tricyclohexylphosphine)benzylidene ruthenium (IV) dichloride, CH₂Cl₂, reflux; (c) *m*-CPBA, CH₂Cl₂; (d) NaN₃, NH₄Cl, CH₃OH, H₂O; (e) TEA, 1,3-propanedithiol, CH₃OH.

15

44

AB2
181

Scheme 2




- 5 **Reagents and conditions:** (a) Di-*tert*-butyldicarbonate, THF; (b) H_2 , 10% Pd/C, EtOAc; (c) 2-pyridylsulfonyl chloride, TEA, DMF; (d) HCl, EtOAc; (e) N-Boc-cyclohexylalanine, P-EDC, CH_2Cl_2 ; (f) HCl, CH_2Cl_2 ; (g) benzofuran-2-carboxylic acid, P-EDC, CH_2Cl_2 ; (h) Dess-Martin periodinane, methylene chloride.

10 The deuterated compound of the Example 7 may be conveniently prepared according to Scheme 3. The skilled artisan will understand from Example 7 and Scheme 3 how to make any of the the deuterated compounds of the present invention.

The individual diastereomers of benzofuran-2-carboxylic acid {(S)-3-methyl-1-[(2,2',4'-trideuterio)-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide 16
15 and 17 may be prepared as outlined in Scheme 3

42

Scheme 3


Reagents and Conditions: a.) CD₃OD:D₂O (10:1), TEA; b.) HPLC separation.

5

Treatment of the diastereomeric ketones 15 with triethylamine in CD₃OD:D₂O at reflux provides the deuterated analog as a mixture of diastereomers which are separated by HPLC to provide the deuterated compounds 16 and 17.

189
183

Scheme 4




- In Scheme 4, carbobenzyloxy-D-alaninol (Cbz-D-alaninol) is first converted to an iodide, then is reacted with allyl Grignard with a copper (I) catalyst or a similar allyl organometallic reagent. The amine is then alkylated with allyl iodide. Grubbs' catalyst is then used to form the azapine ring by ring closing metathesis. Epoxidation of the alkene followed by separation of the diastereomers followed by opening of the epoxide of the minor component with sodium azide provides the intermediate azido alcohol. Reduction of the azide followed by acylation of the amine with a protected amino acid such as Boc-cyclohexylalanine, followed by deprotection of the Cbz gives the intermediate secondary amine, which is then sulfonylated with a sulfonyl chloride such as pyridine sulfonyl sulfonyl chloride. Deprotection of the Boc group followed by acylation with an acylating agent such

48f

as 2-furan carboxylic acid, HBTU, NMM, and final oxidation of the secondary alcohol to the ketone provides the desired products.

Scheme 5



Intermediate (S)-3-Cyclohexyl-N-((3S,4S,7R)-3-hydroxy-7-methyl-azepan-4-yl)-2-methyl-propionamide, as described in Scheme 4, is reductively aminated with an aldehyde or a ketone such as propionaldehyde, then treated with a reducing agent such as sodium borohydride. Deprotection of the Boc group followed by acylation with an acylating agent such as 2-furan carboxylic acid, HBTU, NMM, and final oxidation of the secondary alcohol to the ketone provides the desired products.

The starting materials used herein are commercially available amino acids or are prepared by routine methods well known to those of ordinary skill in the art and can be found in standard reference books, such as the COMPENDIUM OF ORGANIC SYNTHETIC METHODS, Vol. I-VI (published by Wiley-Interscience).

Coupling methods to form amide bonds herein are generally well known to the art. The methods of peptide synthesis generally set forth by Bodansky *et al.*, THE PRACTICE OF PEPTIDE SYNTHESIS, Springer-Verlag, Berlin, 1984; E. Gross and J. Meienhofer, THE PEPTIDES, Vol. 1, 1-284 (1979); and J.M. Stewart and J.D. Young, SOLID PHASE PEPTIDE SYNTHESIS, 2d Ed., Pierce Chemical Co., Rockford, Ill., 1984. are generally illustrative of the technique and are incorporated herein by reference.

19X
185

Synthetic methods to prepare the compounds of this invention frequently employ protective groups to mask a reactive functionality or minimize unwanted side reactions. Such protective groups are described generally in Green, T.W, PROTECTIVE GROUPS IN ORGANIC SYNTHESIS, John Wiley & Sons, New York (1981). The term "amino protecting groups" generally refers to the Boc, acetyl, benzoyl, Fmoc and Cbz groups and derivatives thereof as known to the art. Methods for protection and deprotection, and replacement of an amino protecting group with another moiety are well known.

Acid addition salts of the compounds of Formula I are prepared in a standard manner in a suitable solvent from the parent compound and an excess of an acid, such as hydrochloric, hydrobromic, hydrofluoric, sulfuric, phosphoric, acetic, trifluoroacetic, maleic, succinic or methanesulfonic. Certain of the compounds form inner salts or zwitterions which may be acceptable. Cationic salts are prepared by treating the parent compound with an excess of an alkaline reagent, such as a hydroxide, carbonate or alkoxide, containing the appropriate cation; or with an appropriate organic amine. Cations such as Li^+ , Na^+ , K^+ , Ca^{++} , Mg^{++} and NH_4^+ are specific examples of cations present in pharmaceutically acceptable salts. Halides, sulfate, phosphate, alkanonates (such as acetate and trifluoroacetate), benzoates, and sulfonates (such as mesylate) are examples of anions present in pharmaceutically acceptable salts.

The methods of the present invention may be practiced by administering a pharmaceutical composition which comprises one or more compounds according to Formula I and a pharmaceutically acceptable carrier, diluent or excipient. Accordingly, the compounds of Formula I may be used in the manufacture of a medicament. Pharmaceutical compositions of the compounds of Formula I prepared as hereinbefore described may be formulated as solutions or lyophilized powders for parenteral administration. Powders may be reconstituted by addition of a suitable diluent or other pharmaceutically acceptable carrier prior to use. The liquid formulation may be a buffered, isotonic, aqueous solution. Examples of suitable diluents are normal isotonic saline solution, standard 5% dextrose in water or buffered sodium or ammonium acetate solution. Such formulation is especially suitable for parenteral administration, but may also be used for oral administration or contained in a metered dose inhaler or nebulizer for insufflation. It may be desirable to add excipients such as polyvinylpyrrolidone, gelatin, hydroxy cellulose, acacia, polyethylene glycol, mannitol, sodium chloride or sodium citrate.

46

50273811.030701

186

Alternately, these compounds may be encapsulated, tableted or prepared in an emulsion or syrup for oral administration. Pharmaceutically acceptable solid or liquid carriers may be added to enhance or stabilize the composition, or to facilitate preparation of the composition. Solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, magnesium stearate or stearic acid, talc, pectin, acacia, agar or gelatin. Liquid carriers include syrup, peanut oil, olive oil, saline and water. The carrier may also include a sustained release material such as glyceryl monostearate or glyceryl distearate, alone or with a wax. The amount of solid carrier varies but, preferably, will be between about 20 mg to about 1 g per dosage unit. The pharmaceutical preparations are made following the conventional techniques of pharmacy involving milling, mixing, granulating, and compressing, when necessary, for tablet forms; or milling, mixing and filling for hard gelatin capsule forms. When a liquid carrier is used, the preparation will be in the form of a syrup, elixir, emulsion or an aqueous or non-aqueous suspension. Such a liquid formulation may be administered directly p.o. or filled into a soft gelatin capsule.

For rectal administration, the compounds of this invention may also be combined with excipients such as cocoa butter, glycerin, gelatin or polyethylene glycols and molded into a suppository.

Utility of the Present Invention

The compounds of Formula I are useful as inhibitors of cathepsin S. The present invention provides methods of treatment of diseases caused by pathological levels of cathepsin S, which methods comprise administering to an animal, particularly a mammal, most particularly a human in need thereof a therapeutically effective amount of an inhibitor of cathepsin S, including one or more compounds of the present invention.

The present invention particularly provides methods for treating the following diseases in which cathepsin S is implicated:

treatment and/or prevention of an autoimmune disease state such as rheumatoid arthritis, multiple sclerosis, juvenile-onset diabetes, systemic lupus erythematosus, discoid lupus erythematosus, pemphigus vulgaris, pemphigoid, Grave's disease, myasthenia gravis, Hashimoto's thyroiditis, scleroderma, dermatomyositis, Addison's disease, pernicious anemia, primary myxoedema, thyrotoxicosis, autoimmune atrophic gastritis, stiff-man syndrome, Goodpasture's syndrome, sympathetic ophthalmia, phacogenic uveitis, autoimmune haemolytic anaemia, idiopathic thrombocytopenic purpura, idiopathic leucopenia, primary biliary cirrhosis, active chronic hepatitis, cryptogenic cirrhosis, ulcerative colitis, Sjogren's syndrome, and mixed connective tissue disease;

47

60273811-030701

XZ
187

treatment and/or prevention of a disease state caused by the formation and/or complications of atherosclerotic lesions;

diseases which require for therapy:

- inhibition of a class II MHC-restricted immune response;
- 5 inhibition of an asthmatic response;
- inhibition of an allergic response;
- inhibition of immune response against transplanted organ or tissue; and
- inhibition of elastase activity in atheroma.

10 The present methods contemplate the use of one or more compounds of Formula I, alone or in combination with other therapeutic agents.

For acute therapy, parenteral administration of a compound of Formula I is preferred. An intravenous infusion of the compound in 5% dextrose in water or normal saline, or a similar formulation with suitable excipients, is most effective, although an
15 intramuscular bolus injection is also useful. Typically, the parenteral dose will be about 0.01 to about 100 mg/kg; preferably between 0.1 and 20 mg/kg, in a manner to maintain the concentration of drug in the plasma at a concentration effective to inhibit cathepsin S. The compounds are administered one to four times daily at a level to achieve a total daily dose of about 0.4 to about 400 mg/kg/day. The precise amount of an inventive compound which
20 is therapeutically effective, and the route by which such compound is best administered, is readily determined by one of ordinary skill in the art by comparing the blood level of the agent to the concentration required to have a therapeutic effect.

The compounds of Formula I may also be administered orally to the patient, in a manner such that the concentration of drug is sufficient to inhibit bone resorption or to
25 achieve any other therapeutic indication as disclosed herein. Typically, a pharmaceutical composition containing the compound is administered at an oral dose of between about 0.1 to about 50 mg/kg in a manner consistent with the condition of the patient. Preferably the oral dose would be about 0.5 to about 20 mg/kg.

No unacceptable toxicological effects are expected when compounds of Formula I
30 are administered in accordance with the present methods.

48

60273811.030701

195
188

Biological Assays

The compounds used in the present methods may be tested in one of several biological assays to determine the concentration of compound which is required to have a given pharmacological effect.

5

Determination of cathepsin S proteolytic catalytic activity

All assays for cathepsin S were carried out with human recombinant enzyme. Standard assay conditions for the determination of kinetic constants used a fluorogenic peptide substrate, typically Cbz-Val-Val-Arg-AMC, and were determined in 100 mM Na acetate at pH 5.5 containing 20 mM cysteine and 5 mM EDTA. Stock substrate solutions were prepared at concentrations of 10 or 20 mM in DMSO with 20 μ M final substrate concentration in the assays. All assays contained 10% DMSO. All assays were conducted at ambient temperature. Product fluorescence (excitation at 360 nm; emission at 460 nm) was monitored with a Perceptive Biosystems Cytofluor II fluorescent plate reader. Product progress curves were generated over 20 to 30 minutes following formation of AMC product.

15

Inhibition studies

Potential inhibitors were evaluated using the progress curve method. Assays were carried out in the presence of variable concentrations of test compound. Reactions were initiated by addition of enzyme to buffered solutions of inhibitor and substrate. Data analysis was conducted according to one of two procedures depending on the appearance of the progress curves in the presence of inhibitors. For those compounds whose progress curves were linear, apparent inhibition constants ($K_{i,app}$) were calculated according to equation 1 (Brandt *et al.*, *Biochemistry*, 1989, 28, 140):

25

$$v = V_m A / [K_d (1 + I/K_{i,app}) + A] \quad (1)$$

where v is the velocity of the reaction with maximal velocity V_m , A is the concentration of substrate with Michaelis constant of K_d , and I is the concentration of inhibitor.

30

For those compounds whose progress curves showed downward curvature characteristic of time-dependent inhibition, the data from individual sets was analyzed to give k_{obs} according to equation 2:

35

$$[AMC] = v_{ss} t + (v_0 - v_{ss}) [1 - \exp(-k_{obs} t)] / k_{obs} \quad (2)$$

49

50273811.030701

195
189

where [AMC] is the concentration of product formed over time t , v_0 is the initial reaction velocity and v_{ss} is the final steady state rate. Values for k_{obs} were then analyzed as a linear function of inhibitor concentration to generate an apparent second order rate constant (k_{obs} / inhibitor concentration or $k_{obs} / [I]$) describing the time-dependent inhibition. A complete discussion of this kinetic treatment has been fully described (Morrison *et al.*, *Adv. Enzymol. Relat. Areas Mol. Biol.*, 1988, 61, 201).

General

Nuclear magnetic resonance spectra were recorded at either 250 or 400 MHz using, respectively, a Bruker AM 250 or Bruker AC 400 spectrometer. $CDCl_3$ is deuteriochloroform, $DMSO-d_6$ is hexadeuteriodimethylsulfoxide, and CD_3OD is tetradeuteriomethanol. Chemical shifts are reported in parts per million (δ) downfield from the internal standard tetramethylsilane. Abbreviations for NMR data are as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublets, dt = doublet of triplets, app = apparent, br = broad. J indicates the NMR coupling constant measured in Hertz. Continuous wave infrared (IR) spectra were recorded on a Perkin-Elmer 683 infrared spectrometer, and Fourier transform infrared (FTIR) spectra were recorded on a Nicolet Impact 400 D infrared spectrometer. IR and FTIR spectra were recorded in transmission mode, and band positions are reported in inverse wavenumbers (cm^{-1}). Mass spectra were taken on either VG 70 FE, PE Syx API III, or VG ZAB HF instruments, using fast atom bombardment (FAB) or electrospray (ES) ionization techniques. Elemental analyses were obtained using a Perkin-Elmer 240C elemental analyzer. Melting points were taken on a Thomas-Hoover melting point apparatus and are uncorrected. All temperatures are reported in degrees Celsius.

Analtech Silica Gel GF and E. Merck Silica Gel 60 F-254 thin layer plates were used for thin layer chromatography. Both flash and gravity chromatography were carried out on E. Merck Kieselgel 60 (230-400 mesh) silica gel.

Where indicated, certain of the materials were purchased from the Aldrich Chemical Co., Milwaukee, Wisconsin, Chemical Dynamics Corp., South Plainfield, New Jersey, and Advanced Chemtech, Louisville, Kentucky.

Examples

In the following synthetic examples, temperature is in degrees Centigrade ($^{\circ}C$). Unless otherwise indicated, all of the starting materials were obtained from commercial sources. Without further elaboration, it is believed that one skilled in the art can, using the

JP

60273841.030701


190

preceding description, utilize the present invention to its fullest extent. These Examples are given to illustrate the invention, not to limit its scope. Reference is made to the claims for what is reserved to the inventors hereunder.

5

Example 1

Preparation of Benzofuran-2-carboxylic acid (S)-2-cyclohexyl-1-(3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl-ethyl)-amide.

a.) **Allyl-pent-4-enyl-carbamic acid benzyl ester**

10 To a suspension of NaH (1.83 g, 76.33 mmol of 90% NaH) in DMF was added benzyl allyl-carbamic acid benzyl ester (7.3 g, 38.2 mmol) in a dropwise fashion. The mixture was stirred at room temperature for approximately 10 minutes whereupon 5-bromo-1-pentene (6.78 mL, 57.24 mmol) was added in a dropwise fashion. The reaction was heated to 40°C for approximately 4 hours whereupon the reaction was partitioned between 15 dichloromethane and water. The organic layer was washed with water (2x's), brine, dried (MgSO₄), filtered and concentrated. Column chromatography of the residue (10% ethyl acetate:hexanes) provided 10.3 grams of the title compound as an oil: MS(EI) 260 (M+H⁺).

b.) **2,3,4,7-Tetrahydro-azepine-1-carboxylic acid benzyl ester**

20 To a solution of compound of Example 1a (50 g) in dichloromethane was added bis(tricyclohexylphosphine)benzylidene ruthenium (IV) dichloride (5.0 g). The reaction was heated to reflux until complete as determined by TLC analysis. The reaction was concentrated *in vacuo*. Column chromatography of the residue (50% dichloromethane:hexanes) gave 35 g of the title compound: MS(EI) 232 (M+H⁺).

25

c.) **8-Oxa-3-aza-bicyclo[5.1.0]octane-3-carboxylic acid benzyl ester**

To a solution of the compound of Example 1b (35 g, 1.5 mol) in CH₂Cl₂ was added *m*-CPBA (78 g, 0.45 mol). The mixture was stirred overnight at room temperature whereupon it was filtered to remove the solids. The filtrate was washed with water and 30 saturated NaHCO₃ (several times). The organic layer was dried (MgSO₄), filtered and concentrated to give 35 g of the title compound which was of sufficient purity to use in the next step: MS(EI) 248 (M+H⁺), 270 (M+Na⁺).

5

60273811.030701

d.) 4-azido-3-hydroxy-azepane-1-carboxylic acid benzyl ester

To a solution of the epoxide from Example 1c (2.0 g, 8.1 mmol) in methanol:water (8:1 solution) was added NH_4Cl (1.29 g, 24.3 mmol) and sodium azide (1.58 g, 24.30 mmol). The reaction was heated to 40°C until complete consumption of the starting epoxide was observed by TLC analysis. The majority of the solvent was removed *in vacuo* and the remaining solution was partitioned between ethyl acetate and pH 4 buffer. The organic layer was washed with sat. NaHCO_3 , water, brine dried (MgSO_4), filtered and concentrated. Column chromatography (20% ethyl acetate:hexanes) of the residue provided 1.3 g of the title compound: MS(EI) 291 ($\text{M}+\text{H}^+$) plus 0.14 g of trans-4-hydroxy-3-azido-hexahydro-1H-azepine

e.) 4-amino-3-hydroxy-azepane-1-carboxylic acid benzyl ester

To a solution of the azido alcohol of Example 1d (1.1 g, 3.79 mmol) in methanol was added triethylamine (1.5 mL, 11.37 mmol) and 1,3-propanedithiol (1.1 mL, 11.37 mL). The reaction was stirred until complete consumption of the starting material was observed by TLC analysis whereupon the reaction was concentrated *in vacuo*. Column chromatography of the residue (20% methanol:dichloromethane) provided 0.72 g of the title compound: MS(EI) 265 ($\text{M}+\text{H}^+$).

f.) 4-*tert*-Butoxycarbonylamino-3-hydroxy-azepane-1-carboxylic acid benzyl ester

To a stirring solution of 4-amino-3-hydroxy-azepane-1-carboxylic acid benzyl ester (Example 1e, 1.04 g, 3.92 mmol) in THF was added di-*tert*-butyldicarbonate (0.864 g). After stirring at room temperature for 30 minutes, the reaction mixture was diluted with diethylether and extracted with saturated NaHCO_3 . The organic layer was dried over anhydrous Na_2SO_4 , filtered, concentrated, and purified by silica gel column to give the title compound as a yellow oil (0.963 g, 2.64 mmol, 67%). MS (ESI): 365.03 ($\text{M}+\text{H}^+$).

g.) 3-Hydroxy-azepan-4-yl-carbamic acid-*tert*-butyl ester

To a solution of 4-*tert*-butoxycarbonylamino-3-hydroxy-azepane-1-carboxylic acid benzyl ester (Example 1f, 0.963 g, 2.64 mmol) in ethyl acetate (16 mL) was added 10% palladium on carbon (500 mg). After stirring the solution at room temperature for 48 hours, the mixture was filtered through celite. The filtrate was concentrated to yield the title compound (0.529 g, 2.29 mmol, 87%). MS(ESI): 231.92 ($\text{M}+\text{H}^+$).

192

h.) 3-Hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-yl-carbamic acid-*tert*-butyl ester

To a solution of 3-hydroxy-azepan-4-yl-carbamic acid-*tert*-butyl ester (Example 1g, 0.529, 2.29 mmol) in DCM (20 mL) was added triethylamine (232 mg) and pyridine-2-sulfonyl chloride (410 mg, 2.32 mmol). After stirring at room temperature for 30 minutes, the mixture was washed with saturated NaHCO₃. The organic layer was dried, filtered, concentrated and purified on a silica gel column to give the title compound as a solid (0.583g, 1.57mmol, 68%).

MS(ESI): 372.95 (M+H⁺).

10 i.) 4-Amino-1-(pyridine-2-sulfonyl)-azepan-3-ol

To a stirring solution of 3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-yl-carbamic acid-*tert*-butyl ester (Example 1h, 0.583 g, 1.57mmol) in ethyl acetate (0.5 mL) was added HCl (4M in dioxane) (3.9 mL). After stirring the reaction mixture for 30 minutes at room temperature, the mixture was concentrated to yield a white solid. The solid was treated with NaOH and then extracted with ethylacetate. The organic layer was dried, filtered, and concentrated to yield a yellow solid (0.347 g, 1.28 mmol, 81%).

MS (ESI) 272.93 (M+H⁺).

20 j.) ((S)-2-Cyclohexyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoylethyl]-carbamic acid-*tert*-butyl ester

To a solution of 4-amino-1-(pyridine-2-sulfonyl)-azepan-3-ol (Example 1i, 19 mg, 0.070 mmol) in CH₂Cl₂ was added N-Boc-cyclohexylalanine (28.5 mg, 0.106mmol), 1-hydroxybenzotriazole (16.1 mg, 0.12 mmol), and P-BDC (140 mg, 0.14 mmol) in CH₂Cl₂. After shaking at room temperature overnight, the mixture was treated with PS-Trisamine.

25 After shaking for another 2 hours, the mixture was filtered and concentrated to yield the title compound as a solid. MS (ESI) 525 (M+H⁺).

k.) (S)-2-Amino-3-cyclohexyl-N-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-yl]-propionamide

30 To a stirring solution of ((S)-2-cyclohexyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoylethyl]-carbamic acid-*tert*-butyl ester (Example 1j, 34 mg, 0.07 mmol) in CH₂Cl₂ (0.50 mL) was added HCl (4M in dioxane) (0.165 mL). After stirring at room temperature for 30 minutes, the mixture was concentrated, giving a white solid. The white solid was azeotroped with toluene then treated with MP-carbonate (0.35 mmol) in methanol. After four hours of shaking, the mixture was filtered and concentrated to give the title compound as a solid. MS(ESI) 425.03 (M+H⁺).

J3

ED273811-030701

1.) Benzofuran-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide

To a solution of (S)-2-amino-3-cyclohexyl-N-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-yl]-propionamide (Example 1k, 27 mg, 0.070 mmol) in CH_2Cl_2 was added benzofuran-2-carboxylic acid (17.0 mg, 0.106 mmol), 1-hydroxybenzotriazole (16.1 mg, 0.12 mmol), and P-EDC (140 mg, 0.14 mmol) in CH_2Cl_2 . After shaking at room temperature overnight, the mixture was treated with PS-Trisamine. After shaking for another 2 hours, the mixture was filtered and concentrated to yield the title compound as a solid. MS (ESI) 568.79 ($\text{M}+\text{H}^+$).

m.) Benzofuran-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide


To a stirring solution of benzofuran-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide (Example 1l, 37 mg, .070 mmol) in CH_2Cl_2 (0.5 mL) was added Deas-Martin reagent (45 mg, 0.105 mmol). After stirring for 30 minutes, solutions of sodium thiosulfate (10% in water, 0.50 mL) and saturated aqueous sodium bicarbonate (0.50 mL) were added simultaneously to the reaction. The mixture was then extracted with dichloromethane (2 times). The organic layer was dried, filtered, and concentrated. The residue was purified on a preparative R,R-Whelk-O column by HPLC to yield the two diastereomers of the title compound as solids (first eluting: 4.5mg, second eluting: 4.5 mg). MS (ESI) 566.87 ($\text{M}+\text{H}^+$); ^1H NMR (400Hz, CDCl_3): δ 8.67(m), 7.95(m), 7.63(m), 7.50(m), 7.02(m), 6.83(m), 5.25(m), 4.76(m), 4.14(t), 3.88(d), 2.74(m), 2.16(m), 1.88(m), 1.66-0.94(m).

25

50273811-030701

Example 2

Preparation of 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[(R)-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide




5 Following the procedure of Example 1(l) – 1(m) except substituting 5-(3-trifluoromethylphenyl)-furan-2-carboxylic acid for benzofuran-2-carboxylic acid in step 1(l), the title compound was purified to yield two diastereomers as solids:

¹H-NMR (400Hz, CDCl₃): δ 8.67(m), 7.93(m), 7.58(m), 7.24(m), 6.83(m), 5.18(m), 4.76(m), 4.27(t), 3.85(d), 2.78(m), 2.16(m), 1.85(m), 1.52-1.02(m).

10

Example 3

Preparation of 5-(4-Chloro-phenyl)-furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[(3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide




15 Following the procedure of Example 1(l) – 1(m), except substituting 5-(4-chlorophenyl)-furan-2-carboxylic acid for 2-benzofurancarboxylic acid in step 1(l), the title compound was purified to yield two diastereomers as solids: ¹H-NMR (400Hz, CDCl₃): δ 8.62(m), 7.93(m), 7.65(d), 7.47(m), 7.38(t), 7.20(m), 6.92(m), 6.72(d), 5.18(m), 4.77(m), 4.09(t), 3.84(d), 2.73(m), 2.33-1.02(m).

20

Example 4

Preparation of 5-(4-Chloro-phenyl)-furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[(3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide




25 Following the procedure of Example 1(h) – 1(m), except substituting 5-(4-chlorophenyl)-furan-2-carboxylic acid for benzofuran-2-carboxylic acid in step 1(l) and 2-pyridine-N-oxide sulfonyl chloride for pyridine-2-sulfonyl chloride in step 1(h), the title

compound was purified to yield two diastereomers as solids: $^1\text{H-NMR}$ (400Hz, CDCl_3): δ 8.26(m), 8.12(t), 7.73-7.21(m), 6.76(t), 5.09(m), 4.82(m), 4.10(d), 3.88(dd), 3.54(s), 2.79(m), 2.19-1.02(m).

5

Example 5

Preparation of 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid [(S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl]-amide




Following the procedure of Example 1(h) - 1(m), except 5-(3-trifluoromethyl-phenyl)-furan-2-carboxylic acid for 2-benzofurancarboxylic acid in step 1(l) and 2-pyridine-N-oxide sulfonyl chloride for pyridine-2-sulfonyl chloride in step 1(h), the title compound was purified to yield two diastereomers as solids: $^1\text{H-NMR}$ (400Hz, CDCl_3): δ 8.26(m), 8.11(t), 8.02-7.23(m), 6.86(t), 5.11(m), 4.82(m), 4.14(t), 3.90-3.85(d), 3.16(s), 3.88(m), 2.25-1.02(m).

15

Example 6

Preparation of 5,6-Dimethoxy-benzofuran-2-carboxylic acid [(S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl]-amide




Following the procedure of Example 1(h) - 1(m), except 5,6-dimethoxy-benzofuran-2-carboxylic acid in step 1(l) and 2-pyridine-N-oxide sulfonyl chloride for pyridine-2-sulfonyl chloride in step 1(h), the title compound was purified to yield two diastereomers as solids: $^1\text{H-NMR}$ (400Hz, CDCl_3): δ 8.25-7.37(m), 7.07(d), 5.02(m), 4.88(m), 4.12(d), 3.96(s), 3.94(s), 3.84(d), 3.73(s), 2.86(t), 2.20(m), 1.94-1.02(m).

25

Example 7

Preparation of Benzo[*b*]furan-2-carboxylic acid ((*S*)-3-methyl-1-[(2,2',4'-trideuterio)-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl)amide



- 5 a.) 4-((*S*)-2-*tert*-Butoxycarbonylamino-4-methyl-pentanoylamino)-3-hydroxy-azepan-1-carboxylic acid benzyl ester

To a solution of 4-amino-3-hydroxy-azepane-1-carboxylic acid benzyl ester of Example 1e (720 mg, 2.72 mmol) in CH₂Cl₂ was added EDC (521 mg), HOBt (368 mg) and N-Boc-leucine (630 mg). The reaction was maintained at room temperature until
10 complete consumption of the starting material was observed by TLC analysis. The reaction was diluted with ethyl acetate and washed with 1N HCl, sat. K₂CO₃, water, brine, dried (MgSO₄), filtered and concentrated. Column chromatography of the residue (3% methanol:dichloromethane) gave 1.0 g of the title compound: MS(EI) 478 (M+H⁺).

- 15 b.) ((*S*)-1-(3-Hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl)-carbamic acid *tert* butyl ester

To a solution of the compound of Example 7a (1.0 g) and 10% Pd/C (catalytic) in ethyl acetate:methanol (2:1 solution) was affixed a balloon of hydrogen. The reaction was stirred until complete consumption of the starting material was observed by TLC analysis.
20 The reaction was filtered to remove the catalyst and the filtrate was concentrated *in vacuo* to provide 0.82 g of the title compound: MS(EI) 344 (M+H⁺).

- c.) ((*S*)-1-[3-Hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-butyl)-carbamic acid *tert*-butyl ester

25 Generation of 2-pyridinesulfonylchloride: A solution of 2-mercaptopyridine (2.23 g in 33 ml 9N HCl) was cooled to 0°C. Chlorine gas was bubbled into the solution for 90 min, taking care to maintain the temperature at 0°C. Ice cooled ethyl acetate was added followed by slow addition of ice cooled sat'd NaHCO₃ until the pH of the water layer was approximately 9. The organic layer were then washed with brine and dried over MgSO₄.
30 Evaporation of the ethyl acetate gave 3.5g of the crude 2-pyridinesulfonylchloride as a light yellow liquid.

197

To a solution of [(S)-1-(3-hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]-carbamic acid *tert* butyl ester of Example 7b (12 g, 34.93 mmol) in dichloromethane was added triethylamine (5.8 mL, 41.92 mmol) followed by the dropwise addition of 2-pyridinesulfonylchloride (7.45 g, 41.92 mmol). The reaction was stirred until complete as determined by TLC analysis. The mixture was then washed with sat. NaHCO₃, water, brine, dried (Na₂SO₄), filtered and concentrated. Column chromatography (75% ethyl acetate:hexanes to 100% ethyl acetate) of the residue provided 15 g of the title compound: MS 484 (M⁺)

- 10 d.) (S)-2-Amino-4-methyl-pentanoic acid-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide

To a solution of [(S)-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-butyl]-carbamic acid *tert*-butyl ester of Example 7c (14.3 g) in methanol was added 4 M HCl in dioxane. The reaction was stirred at room temperature until complete as determined by TLC analysis whereupon it was concentrated to provide 14 g of the title compound: MS (EI) 385 (M+H⁺).

- 15 e.) Benzofuran-2-carboxylic acid [(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl]amide

20 To a solution of (S)-2-amino-4-methyl-pentanoic acid [3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide of Example 7d (0.15 g) in dichloromethane was added TEA (0.11 mL), HOBt (49 mg), EDC (69 mg) and benzofuran-2-carboxylic acid (58 mg). The reaction was stirred until complete. Workup and column chromatography (5% methanol:ethyl acetate) provided the title compound: MS(EI) 529 (M+H⁺).

25

E0273811-030701

12

204
198

f.) Benzofuran-2-carboxylic acid ((S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl)amide

To a solution of the alcohol of Example 7e (0.11 g) in DMSO was added TEA (0.17 mL) and pyridine sulfur trioxide complex (99 mg). The reaction was stirred at room temperature for approximately 2 hours whereupon it was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried, filtered and concentrated. Column chromatography of the residue (10% CH₃OH:EtOAc) provided 75 mg of the title compound as a mixture of diastereomers: ¹H NMR (CDCl₃): δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.7 (dd, 1H), 4.0 (m, 1H), 4.7 (m, 2H), 5.0 (m, 1H), 7.2-7.3 (m, 3H), 7.4 (m, 4H), 7.6 (m, 1H), 8.0 (m, 2H), 8.7 (m, 1H); MS(EI): 527 (M+H⁺, 40%).

g.) of Benzofuran-2-carboxylic acid ((S)-3-methyl-1-[(2,2,4-trideuterio)-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl)amide

To a solution of benzofuran-2-carboxylic acid ((S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl)amide of Example 7f (0.03 g) in D₂O-CD₃OD (0.4:4 mL) was added triethylamine (0.04 mL). The reaction was heated to reflux for 2 hours whereupon it was concentrated and dried under vacuum. The residue was the redissolved in the same mixture and heated to reflux overnight. The reaction was concentrated and the residue purified by column chromatography (5% methanol:dichloromethane) to provide the title compound (0.02 g): ¹H NMR: δ 1.0 (m, 6H), 1.5-2.2 (m, 6H), 2.7 (m, 1H), 4.1 (m, 1H), 4.7 (m, 2H), 7.4-8.0 (m, 8H), 8.7 (m, 1H); MS(EI): 529 (M⁺, 45%).


The diastereomeric mixture was separated by HPLC to provide the faster eluting diastereomer: MS(EI): 530 (M+H⁺, 100%) and the slower eluting diastereomer: MS(EI): 530 (M+H⁺, 100%).

59

50273811.030701

Example 8

Furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide



5 a. ((R)-2-Iodo-1-methyl-ethyl)-carbamic acid benzyl ester

Triphenylphosphine (24 g, 91.8 mmol) was added to a solution of imidazole (12.5 g, 184 mmol) in CH_2Cl_2 (231 ml), then was cooled to 0 degrees C. Iodine (23.3 g, 91.8 mmol) was added to the suspension. The reaction mixture turned yellow, then faintly brown. After 5 minutes ((R)-2-hydroxy-1-methyl-ethyl)-carbamic acid benzyl ester (9.59 g, 45.9 mmol) was added and the reaction mixture was warmed to RT then stirred for 3 h. Then, H_2O (7 ml) was added and the reaction mixture was partitioned between CH_2Cl_2 (300 ml) and H_2O (600 ml). The aqueous layer was extracted again with CH_2Cl_2 (200 ml). The combined organic layer was then washed with a solution of 1:9 aq. saturated $\text{Na}_2\text{S}_2\text{O}_3$: H_2O (140 ml), then brine (400 ml). The combined organics were dried with MgSO_4 , filtered, concentrated *in vacuo*, then filtered through a plug of silica gel washing with 15% EtOAc/ hexanes (1.5 liter). The solution was concentrated *in vacuo*, then the solid was washed with hexane and the resultant white solid was used in the next reaction without further purification (11g, 75%).

20 b. ((R)-1-Methyl-pent-4-enyl)-carbamic acid benzyl ester

Copper (I) bromide-dimethyl sulfide (1.93 g, 9.4 mmol) was dissolved in distilled THF (24 ml), then was cooled to -78 degrees C. A solution of allyl magnesium chloride (9.4 ml, 2M in THF, Aldrich) was added dropwise, then the solution was stirred for 30 minutes. ((R)-2-Iodo-1-methyl-ethyl)-carbamic acid benzyl ester (1.5 g, 4.7 mmol) in distilled THF (3 ml) was added dropwise, then the reaction was warmed to -40 degrees C and was stirred for 2.5 h. The reaction mixture was quenched with aq. sat. NH_4Cl (4 ml) at -40 degrees C, warmed to RT and the gray reaction mixture turned sky blue. THF was removed *in vacuo*. Then, Et_2O was added and the reaction mixture was filtered to remove precipitated solids. The solids were washed with additional Et_2O . The combined organics were extracted with 10% NH_4OH (3x), then brine. The combined organics were dried with

226
200

MgSO₄, filtered, concentrated *in vacuo*, then filtered through a plug of silica gel washing with 20% EtOAc/ hexanes (100 ml). The solution was concentrated *in vacuo*, then the resultant colorless oil was used in the next reaction without further purification (0.8 g, 73%).

5 c. Allyl-((R)-1-methyl-pent-4-enyl)-carbamic acid benzyl ester

((R)-1-Methyl-pent-4-enyl)-carbamic acid benzyl ester (790 mg, 3.39 mmol) was dissolved in DMF (8 ml) and was cooled to 0 degrees C. Sodium hydride (60% dispersion, 271 mg, 6.78 mmol) was added and the reaction was stirred for 15 minutes. Allyl bromide (1.23 g, 0.88 ml, 10.17 mmol) was added and the reaction mixture was stirred for 3 h at 0
10 degrees C. H₂O (10 ml) was added, then 2N HCl was added dropwise adjusting the pH to 1. The reaction mixture was extracted with Et₂O (2 x 50 ml). The combined organics were washed with aq. 2N HCl, then aq. NaHCO₃, then brine. The combined organics were dried with MgSO₄, filtered, concentrated *in vacuo*, then chromatographed on silica gel (5% EtOAc/ hexanes) to yield the title compound as a colorless oil (883 mg, 95%).

15

d. 2-Methyl-2,3,4,7-tetrahydro-azepine-1-carboxylic acid benzyl ester

Allyl-(1-methyl-pent-4-enyl)-carbamic acid benzyl ester (0.872 g, 3.19 mmol) was dissolved in CH₂Cl₂ (10 ml) and a stream of argon gas was bubbled into the reaction mixture for 10 minutes. Then bis(tricyclohexylphosphine)benzylidene ruthenium(IV)
20 dichloride (Strem Chemicals, Grubbs' catalyst, 19 mg, 0.0227 mmol) was added and the reaction mixture was refluxed for 2 h. Additional bis(tricyclohexylphosphine)benzylidene ruthenium(IV) dichloride (mg, 0.0108 mmol) was added and the reaction mixture was refluxed for an additional 1.5 hours. The reaction was cooled to RT under argon overnight, then was concentrated *in vacuo* by rotary evaporation, then was chromatographed (silica gel,
25 5% EtOAc/ hexanes) to give the title compound (0.72 g, 92%): ¹H NMR: 7.35-7.20 (m, 5H), 5.65 (1H, m), 5.13 (2H, AB), 4.45-4.05 (m, 2H), 3.56 (1H, d), 2.25-2.10 (m, 2H), 1.90-1.60 (m, 2H), 1.12 (3H, d); Liquid Chromatography/Electrospray mass spec: M+H⁺ = 246.2.

30 e. (1S,4R,7R)-4-Methyl-8-oxa-3-aza-bicyclo[5.1.0]octane-3-carboxylic acid benzyl ester

m-Chloro-perbenzoic acid (1.10 g, 57-86% pure) was added to a solution of 2-methyl-2,3,4,7-tetrahydro-azepine-1-carboxylic acid benzyl ester (0.72 g, 2.94 mmol) in CH₂Cl₂ at 0 degrees C. The reaction mixture was stirred for half an hour, then was warmed to RT. Additional m-chloro-perbenzoic acid (0.660 g, 57-86% pure) was added and the reaction was stirred 2 h. The reaction mixture was concentrated *in vacuo* by rotary
35 evaporation, then 80 ml of 9:1 hexanes/EtOAc was added and the reaction mixture was

61

50273811.030701

201

filtered. The filtrate was concentrated *in vacuo* by rotary evaporation, then was chromatographed (silica gel, 20% EtOAc:hexanes) to give (1S,4R,7S)-4-methyl-8-oxa-3-aza-bicyclo[5.1.0]octane-3-carboxylic acid benzyl ester (0.450 g, 75%) and the title compound (0.15 g, 25% yield): ¹H NMR: 7.42-7.22 (m, 5H), 5.13 (2H, s), 4.50-4.15 (m, 2H), 3.27 (1H, d), 3.12-2.95 (1H, m), 2.15-1.70 (m, 2H), 1.47 (m, 2H), 1.12 (3H, d); Liquid Chromatography/Electrospray mass spec: M+H⁺ = 262.0.

f. (2R,5S,6S)-5-Azido-6-hydroxy-2-methyl-azepane-1-carboxylic acid benzyl ester

Sodium azide (0.139 g, 2.14 mmol) was added to a solution of (1S,4R,7R)-4-methyl-8-oxa-3-aza-bicyclo[5.1.0]octane-3-carboxylic acid benzyl ester (0.186 g, 0.71 mmol) and ammonium chloride (0.114 g, 2.14 mmol) in MeOH (1.5 ml) and H₂O (0.15 ml), then was refluxed for 6 h. The reaction mixture was concentrated *in vacuo* by rotary evaporation, then was diluted with water (5 ml) and extracted with EtOAc (10 ml). The organic layer was then extracted with water, brine, dried with MgSO₄, filtered, concentrated *in vacuo* by rotary evaporation, and chromatographed (silica gel, 20% EtOAc/hexanes) to yield the title compound (0.192 g, 89%): 7.39-7.30 (m, 5H), 5.15 (2H, s), 4.10-3.67 (m, 2H), 3.10 (1H, d), 1.85-1.53 (m, 4H), 1.09 (3H, d); Liquid Chromatography/Electrospray mass spec: M+H⁺ = 305.2.

g. (2R,5S,6S)-5-Amino-6-hydroxy-2-methyl-azepane-1-carboxylic acid benzyl ester

Triphenylphosphine (0.25 g, 0.952 mmol) was added to a solution of (2R,5S,6S)-5-azido-6-hydroxy-2-methyl-azepane-1-carboxylic acid benzyl ester (0.193 g, 0.635 mmol) in THF (10 ml) and H₂O (0.04 ml), then was heated to 45 degrees C overnight. The reaction mixture was then diluted with toluene (100 ml x 2) and was azeotroped *in vacuo* by rotary evaporation twice. The resulting oil was dissolved in MeOH and HCl in Et₂O and the resulting salt was collected following filtration and was used in the next reaction without further purification (0.27 g, 90%).

h. (2R,5S, 6S)-5-((S)-2-tert-Butoxycarbonylamino-3-cyclohexyl-propanoylamino)-2-methyl-3-hydroxy-azepane-1-carboxylic acid benzyl ester

1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide (1.0 g, 5.36 mmol) was added to a solution of Boc-cyclohexylalanine (1.2 g, 4.45 mmol), 4-methylmorpholine (1.35 g, 1.50 ml, 13.4 mmol), hydroxybenzotriazole (0.72 g, 5.36 mmol), and (2R,5S,6S)-5-Amino-6-hydroxy-2-methyl-azepane-1-carboxylic acid benzyl ester (1.4 g, 4.45 mmol) in DMF (20 ml). The reaction was stirred overnight at RT, then was diluted with EtOAc (100 ml), washed with

62

60273811-030701

28
202

H₂O (50 ml), brine (50 ml), dried with magnesium sulfate, filtered, concentrated *in vacuo* by rotary evaporation, and chromatographed (silica gel, 50% EtOAc/hexanes) to yield the title compound (1.70 g, 72 %): Electrospray mass spec: $M+H^+ = 532.4$

- 5 i. [(S)-2-Cyclohexyl-1-((3S, 4S, 7R)-7-methyl-3-hydroxy-azepan-4-ylcarbamoyl)-ethyl]-carbamic acid tert-butyl ester
(2R,5S, 6S)-5-((S)-2-tert-Butoxycarbonylamino-3-cyclohexyl-propanoylamino)-2-methyl-6-hydroxy-azepan-1-carboxylic acid benzyl ester (1.70 g, 3.20 mmol) was dissolved in ethanol (30 ml). Then 10% Pd/C (0.34 g, 0.32 mmol) was added and the
10 reaction was stirred overnight under a balloon filled with hydrogen gas. The reaction mixture was filtered through Celite, concentrated *in vacuo* by rotary evaporation and was used in the next reaction without further purification (1.2 g): Electrospray mass spec: $M+H^+ = 398.4$.
- 15 j. [(S)-2-Cyclohexyl-1-((3S, 4S, 7R)-7-methyl-3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl)-ethyl]-carbamic acid tert-butyl ester
2-Pyridine sulfonyl chloride (0.53 g, 3.30 mmol) was added to a solution [(S)-2-Cyclohexyl-1-((3S, 4S, 7R)-7-methyl-3-hydroxy-azepan-4-ylcarbamoyl)-ethyl]-carbamic acid tert-butyl ester (1.2 g, 3.00 mmol), triethylamine (1.02 g, 10.0 mmol) in CH₂Cl₂ (20
20 ml) and was stirred at RT for 30 minutes. The reaction mixture was diluted with EtOAc (100 ml), washed with H₂O, brine, dried with magnesium sulfate, filtered, concentrated *in vacuo* by rotary evaporation, and chromatographed (silica gel, 1:1 hexane/EtOAc) to yield the title compound (1.3 g, 80%): Electrospray mass spec: $M+H^+ = 539.2$.
- 25 k. (S)-2-Amino-3-cyclohexyl-N-((3S, 4S, 7R)-7-methyl-3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-yl)-propionamide
HCl in dioxane (4.0 M, 15.0 ml) was added to a stirred solution of [(S)-2-Cyclohexyl-1-((3S, 4S, 7R)-7-methyl-3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl)-ethyl]-carbamic acid tert-butyl ester (1.30 g, 2.40 mmol) in MeOH (5.0 ml).
30 The reaction mixture was stirred for 2h at RT, then was concentrated *in vacuo* by rotary evaporation and was used in the next reaction without further purification (1.2 g).
- l. Furan-2-carboxylic acid [(S)-2-cyclohexyl-1-((3S, 4S, 7R)-7-methyl-3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl)-ethyl]-amide

67

6 273811.030701


1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide (0.069 g, 0.36 mmol) was added to a solution of furan-2-carboxylic acid (0.040 g, 0.36 mmol), (S)-2-Amino-3-cyclohexyl-N-[(3S, 4S, 7R)-7-methyl-3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-yl]-propionamide (0.15 g, 0.30 mmol), diisopropylethylamine (0.15 g, 0.20 ml, 1.2 mmol), hydroxybenztriazole (0.049 g, 0.36 mmol) in DMF (2.0 ml) and was stirred at RT overnight. The reaction mixture was then warmed to RT and was stirred overnight. The reaction mixture was diluted with EtOAc (30 ml), washed with H₂O, brine, dried with magnesium sulfate, filtered, concentrated *in vacuo* by rotary evaporation, and chromatographed (silica gel, 2.5% MeOH/ CH₂Cl₂) to yield the title compound (0.15 g, 95%): Electrospray mass spec: M+H⁺ = 533.2.

m. Furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide

15 Dess-Martin periodinane (0.15 g, 0.35 mmol) was added to a solution of Furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[(3S,4S,7R)-7-methyl-3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide (0.15 g, 0.28 mmol) in CH₂Cl₂ (2.0 ml) and was stirred at RT for 1 h. The solution was washed with 10% aq. Na₂S₂O₃, then aq. sat. NaHCO₃, then brine. Purification by column chromatography (3%MeOH/CH₂Cl₂) gave the title compound (0.12 g, 80%): ¹H NMR: 8.73(d, 1 H), 7.62(m, 2 H), 7.53(m, 2 H), 7.13(s, 1 H), 6.94(d, 1 H), 6.77(d, 1 H), 6.51(m, 1 H), 5.18(m, 1 H), 4.77(d, 1 H), 4.63(m, 1 H), 4.25(m, 1 H), 3.86(d, 1 H), 2.10(m, 2 H), 1.87-0.93(m, 18 H); Electrospray mass spec: M+H⁺ = 531.2.

Example 9

25 Preparation of Benzofuran-2-carboxylic acid ((S)-2-cyclohexyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide




Following the procedure of Example 8 (a-m), except substituting "benzofuran-2-carboxylic acid" for "furan-2-carboxylic acid" gave the title compound: ¹H NMR: 8.74(d, 1 H), 7.96(m, 3 H), 7.55(m, 1 H), 7.42(m, 2 H), 7.28(m, 2 H), 6.77(d, 1 H), 6.51(m, 1 H), 5.14(m,

204

1 H), 4.77(d, 1 H), 4.69(m, 1 H), 4.43(m, 1 H), 3.85(d, 1 H), 2.18(m, 2 H), 1.85-0.98(m, 18 H); Electrospray mass spec: $M+H^+ = 581.3$.

Example 10

- 5 Preparation of Thiophene-3-carboxylic acid ((S)-2-cyclohexyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide




Following the procedure of Example 8 (a-m), except substituting "thiophene-3-carboxylic acid" for "furan-2-carboxylic acid" gave the title compound: 1H NMR: 8.74(d, 1 H),

- 10 8.00(m, 2 H), 7.66(d, 1 H), 7.46(m, 3 H), 7.28(d, 1 H), 6.90(d, 1 H), 5.14(m, 1 H), 4.43(m, 1 H), 3.82(d, 1 H), 2.16(m, 2 H), 1.90-0.96(m, 18 H); Electrospray mass spec: $M+H^+ = 547.2$.

Example 11

- 15 Preparation of 3-Methyl-furo[3,2-b]-pyridine-2-carboxylic acid ((S)-2-cyclohexyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide



Following the procedure of Example 8 (a-m), except substituting "3-methyl-furo[3,2-b]-pyridine-2-carboxylic acid" for "furan-2-carboxylic acid" gave the title compound: 1H


- 20 NMR: 8.75(d, 1 H), 7.98(m, 2 H), 7.55(m, 1 H), 7.40(m, 2 H), 7.33(m, 1 H), 6.75(d, 1 H), 6.50(m, 1 H), 5.09(m, 1 H), 4.79(d, 1 H), 4.68(m, 1 H), 4.47(m, 1 H), 3.87(d, 1 H), 2.55(s, 3 H), 2.17(m, 1 H), 1.93-0.93(m, 19 H); Electrospray mass spec: $M+H^+ = 596.4$.

5

E027381.1-030701

277
205**Example 12**

Preparation of 5-(2-Morpholin-4-yl-ethoxy)-benzofuran-2-carboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide




5

Following the procedure of Example 8 (i-m), except substituting "(3S,4S)-4-Amino-3-hydroxy-azepane-1-carboxylic acid benzyl ester (as described in Marquis, Robert W., et al *J. Med. Chem.* 44 2001) for "(2R,5S,6S)-5-Amino-6-hydroxy-2-methyl-azepane-1-carboxylic acid benzyl ester" and "5-(2-Morpholin-4-yl-ethoxy)-benzofuran-2-carboxylic acid" for "furan-2-carboxylic acid" gave the title compound: ¹H NMR: 8.54(s, 1H), 8.00(m, 2 H), 7.55-7.05(m, 7 H), 5.16(m, 1 H), 4.81-3.52(m, 15 H), 3.14(br, 2 H), 2.71(t, 1 H), 2.21-0.95(m, 16 H); Electrospray mass spec: M+H⁺ = 712.4.

10

Example 13

15 Preparation of 4-Methyl-2-pyridin-2-yl-thiazole-5-carboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide



20

Following the procedure of Example 8 (i-m), except substituting "(3S,4S)-4-Amino-3-hydroxy-azepane-1-carboxylic acid benzyl ester" for "(2R,5S,6S)-5-Amino-6-hydroxy-2-methyl-azepane-1-carboxylic acid benzyl ester" and "4-Methyl-2-pyridin-2-yl-thiazole-5-carboxylic acid" for "furan-2-carboxylic acid" gave the title compound: ¹H NMR: 8.66(d, 1 H), 8.55(d, 1 H), 7.98(m, 2 H), 7.65(m, 2 H), 7.50(m, 2 H), 7.44(m, 1 H), 7.31(t, 1 H), 7.06(d, 1 H), 5.17(m, 1 H), 4.79(m, 1 H), 4.65(d, 2 H), 4.00(d, 1 H), 3.83(d, 1 H), 2.75(t, 1 H), 2.59(s, 3H), 2.40(m, 2 H), 1.84-0.90(m, 15 H); Electrospray mass spec: M+H⁺ = 625.4.


25

66

60273811-030701

282
206**Example 14**

Preparation of 5-Pyridin-2-yl-thiophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide




5

Following the procedure of Example 8 (i-m), except substituting "(3S,4S)-4-Amino-3-hydroxy-azepan-1-carboxylic acid benzyl ester" for "(2R,5S,6S)-5-Amino-6-hydroxy-2-methyl-azepan-1-carboxylic acid benzyl ester" and "5-Pyridin-2-yl-thiophene-2-carboxylic acid" for "furan-2-carboxylic acid" gave the title compound: ¹H NMR: 8.68(d, 1 H), 8.54(d, 1 H), 7.93(m, 2 H), 7.71(m, 2 H), 7.53(m, 2 H), 7.48(m, 1 H), 7.31(t, 1 H), 7.03(d, 1 H), 5.16(m, 1 H), 4.78(m, 1 H), 4.65(d, 2 H), 4.10(d, 1 H), 3.82(d, 1 H), 2.76(t, 1 H), 2.40(m, 2 H), 1.88-0.89(m, 15 H); Electrospray mass spec: M+H⁺ = 610.2.

10

Example 15

15 Preparation of Furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide



Following the procedure of Example 8 (i-m), except substituting "(3S,4S)-4-Amino-3-hydroxy-azepan-1-carboxylic acid benzyl ester" for "(2R,5S,6S)-5-Amino-6-hydroxy-2-methyl-azepan-1-carboxylic acid benzyl ester" gave the title compound: ¹H NMR: 8.70-8.68(d, 1H), 7.98(m, 2H), 7.53(m, 2H), 7.16-7.12(m, 2H), 6.81-6.75(m, 1H), 6.53(s, 1H), 5.31-5.10(m, 1H), 4.81-4.68(m, 2H), 4.13-4.09(d, 1H), 3.93-3.80(d, 1H), 2.77-2.69(m, 1H), 2.26-0.90(m, 17H); Electrospray mass spec: M+H⁺ = 517.4.


25

67

60273811.030701

73
207**Example 16**

Preparation of Thiophene-2-carboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide




- 5 Following the procedure of Example 8 (i-m), except substituting "(3S,4S)-4-Amino-3-hydroxy-azepane-1-carboxylic acid benzyl ester" for "(2R,5S,6S)-5-Amino-6-hydroxy-2-methyl-azepane-1-carboxylic acid benzyl ester" and "Thiophene-2-carboxylic acid" for "furan-2-carboxylic acid" gave the title compound: ¹H NMR: 8.70-8.69(d, 1H), 7.99-7.82(m, 2H), 7.60-7.51(m, 3H), 7.12-7.10(m, 2H), 6.55-6.53(d, 1H), 5.14-5.11(m, 1H), 4.78-4.67(m, 2H), 4.10-4.07(d, 1H), 3.89-3.84(d, 1H), 2.81-2.74(m, 1H), 2.26-2.16(m, 2H), 1.86-0.90(m, 15H); Electro spray mass spec: M+H⁺ = 533.2.
- 10

Example 17

Preparation of Thiophene-3-carboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide

- 15




- Following the procedure of Example 8 (i-m), except substituting "(3S,4S)-4-Amino-3-hydroxy-azepane-1-carboxylic acid benzyl ester" for "(2R,5S,6S)-5-Amino-6-hydroxy-2-methyl-azepane-1-carboxylic acid benzyl ester" and "Thiophene-3-carboxylic acid" for "furan-2-carboxylic acid" gave the title compound: ¹H NMR: 8.72-8.71(d, 1H), 8.15-8.00(m, 3H), 7.56-7.30(m, 3H), 7.15-7.12(br, 1H), 6.70(br, 1H), 5.20(m, 1H), 4.90-4.70(m, 2H), 4.15(m, 1H), 3.90(d, 1H), 2.90-2.70(m, 1H), 2.28-0.97(m, 17H); Electro spray mass spec: M+H⁺ = 533.4.
- 20

208

Example 18


Preparation of 5-Methyl-thiophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide



- 5 Following the procedure of Example 8 (i-m), except substituting "(3S,4S)-4-Amino-3-hydroxy-azepane-1-carboxylic acid benzyl ester" for "(2R,5S,6S)-5-Amino-6-hydroxy-2-methyl-azepane-1-carboxylic acid benzyl ester" and "5-Methyl-thiophene-2-carboxylic acid" for "furan-2-carboxylic acid" gave the title compound: ¹H NMR: 8.69-8.67(d, 1H), 7.97-7.90(m, 2H), 7.52-7.28(m, 3H), 6.74-6.49(m, 2H), 5.18-5.08(m, 1H), 4.77-4.63(m, 2H), 4.28-4.26(d, 1H), 3.87-3.80(d, 1H), 2.78-2.66(m, 1H), 2.51(s, 3H), 2.25-0.88(m, 17H);
- 10 Electropray mass spec: M+H⁺ = 547.2.

Example 19

Preparation of 3-Methyl-thiophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide




- 15 Following the procedure of Example 8 (i-m), except substituting "(3S,4S)-4-Amino-3-hydroxy-azepane-1-carboxylic acid benzyl ester" for "(2R,5S,6S)-5-Amino-6-hydroxy-2-methyl-azepane-1-carboxylic acid benzyl ester" and "3-Methyl-thiophene-2-carboxylic acid" for "furan-2-carboxylic acid" gave the title compound: ¹H NMR: 8.69-8.68(d, 1H), 7.97-7.89(m, 2H), 7.53-7.50(m, 1H), 7.32-7.17(m, 2H), 6.91-6.84(d, 1H), 6.34-6.32(d, 1H), 5.16-5.11(m, 1H), 4.79-4.70(m, 2H), 4.31-4.10(d, 1H), 3.85-3.81(d, 1H), 2.76-2.69(m, 1H), 2.55(s, 3H), 2.26-0.89(m, 17H) ; Electropray mass spec: M+H⁺ = 547.2.
- 20

89

50273811.030701

2/5
209**Example 20**


Preparation of 3-Ethoxy-thiophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide



- 5 Following the procedure of Example 8 (i-m), except substituting "(3S,4S)-4-Amino-3-hydroxy-azepane-1-carboxylic acid benzyl ester" for "(2R,5S,6S)-5-Amino-6-hydroxy-2-methyl-azepane-1-carboxylic acid benzyl ester" and "3-Ethoxy-thiophene-2-carboxylic acid" for "furan-2-carboxylic acid" gave the title compound: ¹H NMR: 8.69-8.67(d, 1H), 7.96-7.90(m, 2H), 7.60-7.28(m, 4H), 6.92-6.83(d, 1H), 5.15-5.10(m, 1H), 4.74-4.56(m, 2H), 4.30-4.08(m, 3H), 3.84-3.77(d, 1H), 2.72-2.66(m, 1H), 2.25-0.89(m, 20H); Electrospray mass spec: M+H⁺ = 577.2.

Example 21

Preparation of 4-Bromo-N-[(S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl]-benzamide



- 20 Following the procedure of Example 8 (i-m), except substituting "(3S,4S)-4-Amino-3-hydroxy-azepane-1-carboxylic acid benzyl ester" for "(2R,5S,6S)-5-Amino-6-hydroxy-2-methyl-azepane-1-carboxylic acid benzyl ester" and "4-bromo-benzoic acid" for "furan-2-carboxylic acid" gave the title compound: ¹H NMR: 8.71(d, 1 H), 8.00(m, 2 H), 7.69(d, 2 H), 7.52(m, 3 H), 7.26(d, 1 H), 6.91(d, 1 H), 5.22(m, 1 H), 4.77(m, 2 H), 4.14(d, 1 H), 3.85(d, 1 H), 2.71(t, 1 H), 2.31(m, 2 H), 1.86-0.91(m, 15 H); Electrospray mass spec: M+H⁺ = 605.2.


70

50273814-030701

210

Example 22

Preparation of Cyclobutanecarboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide




- 5 Following the procedure of Example 8 (i-m), except substituting "(3S,4S)-4-Amino-3-hydroxy-azepane-1-carboxylic acid benzyl ester" for "(2R,5S,6S)-5-Amino-6-hydroxy-2-methyl-azepane-1-carboxylic acid benzyl ester" and "Cyclobutanecarboxylic acid" for "furan-2-carboxylic acid" gave the title compound: ¹H NMR: 8.68 (d, 1H), 7.97-7.90(m, 2H), 7.71-7.48(m, 1H), 7.19-7.12(d, 1H), 6.81-6.79(d, 1H), 5.08(m, 1H), 4.72-4.48(m, 2H),
 10 4.05-4.01(d, 1H), 3.86-3.79(d, 1H), 3.11-3.05(m, 1H), 2.80-2.70(m, 1H), 2.32-0.80(m, 23H); Electrospray mass spec: M+H⁺ = 505.4.

Example 23

Preparation of Cyclopentanecarboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide

- 15



- Following the procedure of Example 8 (i-m), except substituting "(3S,4S)-4-Amino-3-hydroxy-azepane-1-carboxylic acid benzyl ester" for "(2R,5S,6S)-5-Amino-6-hydroxy-2-methyl-azepane-1-carboxylic acid benzyl ester" and "Cyclopentanecarboxylic acid" for
 20 "furan-2-carboxylic acid" gave the title compound: ¹H NMR: 8.70-8.69(d, 1H), 7.99-7.92(m, 2H), 7.55-7.51(m, 1H), 7.09-7.08(d, 1H), 5.89-5.87(d, 1H), 5.10(m, 1H), 4.71-4.70(d, 1H), 4.65(m, 1H), 4.07-4.03(d, 1H), 3.89-3.84(d, 1H), 2.82-2.58(m, 2H), 2.15(m, 2H), 1.90-0.89(m, 23H); Electrospray mass spec: M+H⁺ = 519.4.

71


50273 11.030701

22

211

Example 24

Preparation of (S)-Tetrahydro-furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide




- 5 Following the procedure of Example 8 (i-m), except substituting "(3S,4S)-4-Amino-3-hydroxy-azepane-1-carboxylic acid benzyl ester" for "(2R,5S,6S)-5-Amino-6-hydroxy-2-methyl-azepane-1-carboxylic acid benzyl ester" and "(S)-Tetrahydro-furan-2-carboxylic acid" for "furan-2-carboxylic acid" gave the title compound: ¹H NMR: 8.67(d, 1H), 7.96(m, 2H), 7.53(m, 1H), 6.96(m, 2H), 5.13(m, 1H), 4.75(m, 1H), 4.41(m, 2H), 4.07-3.91(m, 4H), 2.68(m, 1H), 2.35-0.92 (m, 21H); Electrospray mass spec: M+H⁺ = 521.4.

Example 25

Preparation of (R)-Tetrahydro-furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide

15




- Following the procedure of Example 8 (i-m), except substituting "(3S,4S)-4-Amino-3-hydroxy-azepane-1-carboxylic acid benzyl ester" for "(2R,5S,6S)-5-Amino-6-hydroxy-2-methyl-azepane-1-carboxylic acid benzyl ester" and "(R)-Tetrahydro-furan-2-carboxylic acid" for "furan-2-carboxylic acid" gave the title compound: ¹H NMR: 8.71(d, 1H), 7.96(m, 2H), 7.53(m, 1H), 7.12(m, 2H), 5.10(m, 1H), 4.72(m, 1H), 4.46(m, 2H), 4.11-3.95(m, 4H), 2.74(m, 1H), 2.35-0.92 (m, 21H); Electrospray mass spec: M+H⁺ = 521.4.

72

60273814.030701

2/2
212**Example 26**

Preparation of Furan-3-carboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide




- 5 Following the procedure of Example 8 (i-m), except substituting "(3S,4S)-4-Amino-3-hydroxy-azepane-1-carboxylic acid benzyl ester" for "(2R,5S,6S)-5-Amino-6-hydroxy-2-methyl-azepane-1-carboxylic acid benzyl ester" and "furan-3-carboxylic acid" for "furan-2-carboxylic acid" gave the title compound: ¹H NMR: 8.70-8.68(d, 1H), 7.99-7.92(m, 3H), 7.54-7.44(m, 2H), 7.19-7.18(d, 1H), 6.59-6.57(m, 2H), 5.14-5.09(m, 1H), 4.79-4.63(m, 2H), 4.07-4.04(d, 1H), 3.89-3.84(d, 1H), 2.83-2.76(m, 1H), 2.23-0.91(m, 17H); Electrospray mass spec: M+H⁺ = 517.4.
- 10

Example 27

Preparation of 5-Pyridin-2-yl-thiophene-2-carboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide

- 15




- Following the procedure of Example 8 (i-m), except substituting "(3S,4S)-4-Amino-3-hydroxy-azepane-1-carboxylic acid benzyl ester" for "(2R,5S,6S)-5-Amino-6-hydroxy-2-methyl-azepane-1-carboxylic acid benzyl ester" and "5-Pyridin-2-yl-thiophene-2-carboxylic acid" for "furan-2-carboxylic acid" and "oxy-pyridine-2-sulfonyl chloride" for "2-pyridine sulfonyl chloride" gave the title compound: ¹H NMR: 8.55(d, 1 H), 8.05(d, 1 H), 8.03(d, 1 H), 7.73-7.09(m, 9 H), 5.06(m, 1 H), 4.80(m, 2 H), 4.11(d, 1 H), 3.84(d, 1 H), 2.90(t, 1 H), 2.22(m, 1 H), 2.10-0.88(m, 15 H); Electrospray mass spec: M+H⁺ = 626.4.
- 20

73

60273611.030701

Example 28


Preparation of 4-Methyl-2-pyridin-2-yl-thiazole-5-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide



- 5 Following the procedure of Example 8 (i-m), except substituting "(3S,4S)-4-Amino-3-hydroxy-azepane-1-carboxylic acid benzyl ester" for "(2R,5S,6S)-5-Amino-6-hydroxy-2-methyl-azepane-1-carboxylic acid benzyl ester" and "4-Methyl-2-pyridin-2-yl-thiazole-5-carboxylic acid" for "furan-2-carboxylic acid" and "oxy-pyridine-2-sulfonyl chloride" for "2-pyridine sulfonyl chloride" gave the title compound: ¹H NMR: 8.53(d, 1 H), 8.08(d, 1 H), 8.03(d, 1 H), 7.77-7.05(m, 9 H), 5.03(m, 1 H), 4.75(m, 2 H), 4.13(d, 1 H), 3.80(d, 1 H), 2.88(t, 1 H), 2.67(s, 3 H), 2.22 (m, 1 H), 2.10-0.88(m, 15 H); Electrospray mass spec: M+H⁺ = 641.4.

Example 29

- 15 Preparation of 5-(2-Morpholin-4-yl-ethoxy)-benzofuran-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide




- Following the procedure of Example 8 (i-m), except substituting "(3S,4S)-4-Amino-3-hydroxy-azepane-1-carboxylic acid benzyl ester" for "(2R,5S,6S)-5-Amino-6-hydroxy-2-methyl-azepane-1-carboxylic acid benzyl ester" and "5-(2-Morpholin-4-yl-ethoxy)-benzofuran-2-carboxylic acid" for "furan-2-carboxylic acid" and "oxy-pyridine-2-sulfonyl chloride" for "2-pyridine sulfonyl chloride" gave the title compound: ¹H NMR: 8.23(br, 1 H), 8.06(d, 2 H), 7.48-7.00(m, 8 H), 5.03(m, 1 H), 4.80(m, 2 H), 4.59(m, 2 H), 4.27(m, 2 H), 4.09-3.33(m, 9 H), 3.29(m, 2 H), 2.80(m, 2 H), 2.27-0.88(m, 14 H); Electrospray mass spec: M+H⁺ = 712.4.

~~220~~
214

Example 30

Preparation of Furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxypyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide



5


Following the procedure of Example 8 (i-m), except substituting "(3S,4S)-4-Amino-3-hydroxy-azepane-1-carboxylic acid benzyl ester" for "(2R,5S,6S)-5-Amino-6-hydroxy-2-methyl-azepane-1-carboxylic acid benzyl ester" and "Furan-2-carboxylic acid" for "furan-2-carboxylic acid" and "oxy-pyridine-2-sulfonyl chloride" for "2-pyridine sulfonyl chloride" gave the title compound: ¹H NMR: 8.24-8.23(d, 1H), 8.14-8.11(m, 1H), 7.50-7.39(m, 3H), 7.14(d, 1H), 7.01-6.99(d, 1H), 6.78-6.76(d, 1H), 6.52-6.51(d, 1H), 5.04-4.91(m, 2H), 4.72-4.66(d, 1H), 4.14-4.10(d, 1H), 3.93-3.88(d, 1H), 2.85-2.79(m, 1H), 2.25-0.94(m, 17H); Electrospray mass spec: M+H⁺ = 533.4.

10

15

Example 31

Preparation of Furan-3-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide



Following the procedure of Example 8 (i-m), except substituting "(3S,4S)-4-Amino-3-hydroxy-azepane-1-carboxylic acid benzyl ester" for "(2R,5S,6S)-5-Amino-6-hydroxy-2-methyl-azepane-1-carboxylic acid benzyl ester" and "Furan-3-carboxylic acid" for "furan-2-carboxylic acid" and "oxy-pyridine-2-sulfonyl chloride" for "2-pyridine sulfonyl chloride" gave the title compound: ¹H NMR: 8.25-8.23(d, 1H), 8.14-8.11(m, 1H), 7.97(s, 1H), 7.51-7.39(m, 3H), 7.04-7.03(d, 1H), 6.67(s, 1H), 6.50-6.48(d, 1H), 5.06-4.88 (m, 2H), 4.74-4.68(m, 1H), 4.13-4.09(d, 1H), 3.93-3.88(d, 1H), 2.86-2.79(m, 1H), 2.23-0.93(m, 17H); Electrospray mass spec: M+H⁺ = 533.4.


20

25

75

22x
215**Example 32**

Preparation of Thiophene-3-carboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide




5

Following the procedure of Example 8 (i-m), except substituting "(3S,4S)-4-Amino-3-hydroxy-azepane-1-carboxylic acid benzyl ester" for "(2R,5S,6S)-5-Amino-6-hydroxy-2-methyl-azepane-1-carboxylic acid benzyl ester" and "Thiophene-3-carboxylic acid" for "furan-2-carboxylic acid" and "oxy-pyridine-2-sulfonyl chloride" for "2-pyridine sulfonyl chloride" gave the title compound: ¹H NMR: 8.24-8.22(d, 1H), 8.12-8.09(m, 1H), 7.95(s, 1H), 7.49-7.19(m, 5H), 6.59-6.57(d, 1H), 5.05-5.01 (m, 1H), 4.83-4.74(m, 2H), 4.10-4.06(d, 1H), 3.92-3.87(d, 1H), 2.91-2.85(m, 1H), 2.26-0.92(m, 17H); Electrospray mass spec: M+H⁺ = 549.4.

15

Example 33

Preparation of Thiophene-2-carboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide




Following the procedure of Example 8 (i-m), except substituting "(3S,4S)-4-Amino-3-hydroxy-azepane-1-carboxylic acid benzyl ester" for "(2R,5S,6S)-5-Amino-6-hydroxy-2-methyl-azepane-1-carboxylic acid benzyl ester" and "Thiophene-2-carboxylic acid" for "furan-2-carboxylic acid" and "oxy-pyridine-2-sulfonyl chloride" for "2-pyridine sulfonyl chloride" gave the title compound: ¹H NMR: 8.24-8.23(d, 1H), 8.13-8.10(m, 1H), 7.58-7.38(m, 4H), 7.11-7.07(m, 2H), 6.79-6.77(d, 1H), 5.04-4.69(m, 3H), 4.12-4.08(d, 1H), 3.92-3.87(d, 1H), 2.85-2.79(m, 1H), 2.21-0.90(m, 17H); Electrospray mass spec: M+H⁺ = 549.4.

76

60273811-030701

22
216**Example 34**


Preparation of 5-Methyl-thiophene-2-carboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide



- 5 Following the procedure of Example 8 (i-m), except substituting "(3S,4S)-4-Amino-3-hydroxy-azepane-1-carboxylic acid benzyl ester" for "(2R,5S,6S)-5-Amino-6-hydroxy-2-methyl-azepane-1-carboxylic acid benzyl ester" and "5-Methyl-thiophene-2-carboxylic acid" for "furan-2-carboxylic acid" and "oxy-pyridine-2-sulfonyl chloride" for "2-pyridine sulfonyl chloride" gave the title compound: ¹H NMR: 8.23-8.22(d, 1H), 8.11-8.08(d, 1H), 7.49-7.24(m, 4H), 6.75-6.74(s, 1H), 6.62-6.60(d, 1H), 5.03-4.71 (m, 3H), 4.09-4.05(d, 1H), 3.90-3.85(d, 1H), 2.88-2.83(m, 1H), 2.67(s, 3H), 2.35-0.88(m, 17H); Electrospray mass spec: M+H⁺ = 563.2.

Example 35

- 15 Preparation of 3-Methyl-thiophene-2-carboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide




- Following the procedure of Example 8 (i-m), except substituting "(3S,4S)-4-Amino-3-hydroxy-azepane-1-carboxylic acid benzyl ester" for "(2R,5S,6S)-5-Amino-6-hydroxy-2-methyl-azepane-1-carboxylic acid benzyl ester" and "3-Methyl-thiophene-2-carboxylic acid" for "furan-2-carboxylic acid" and "oxy-pyridine-2-sulfonyl chloride" for "2-pyridine sulfonyl chloride" gave the title compound: ¹H NMR: 8.23-8.22(d, 1H), 8.11-8.09(d, 1H), 7.49-7.17(m, 4H), 6.93-6.91(s, 1H), 6.27(m, 1H), 5.06-4.70(m, 3H), 4.14-4.11(d, 1H), 3.91-3.86(d, 1H), 2.87-2.81(m, 1H), 2.56(s, 3H), 2.28-0.93 (m, 17H) ; Electrospray mass spec: M+H⁺ = 563.2.

77

23
218**Example 36**


Preparation of 3-Ethoxy-thiophene-2-carboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide



- 5 Following the procedure of Example 8 (i-m), except substituting "(3S,4S)-4-Amino-3-hydroxy-azepane-1-carboxylic acid benzyl ester" for "(2R,5S,6S)-5-Amino-6-hydroxy-2-methyl-azepane-1-carboxylic acid benzyl ester" and "3-Ethoxy-thiophene-2-carboxylic acid" for "furan-2-carboxylic acid" and "oxy-pyridine-2-sulfonyl chloride" for "2-pyridine sulfonyl chloride" gave the title compound: ¹H NMR: 8.24-8.22(d, 1H), 8.11-8.09(d, 1H), 7.60-7.31(m, 5H), 6.88-6.87 (d, 1H), 5.06-4.65(m, 3H), 4.37-4.27(m, 1H), 4.12-4.08(d, 1H), 3.88-3.83(d, 1H), 2.84-2.77(m, 1H), 2.28-0.92(m, 21H); Electrospray mass spec: M+H⁺ = 593.2.
- 10

Example 37

- 15 Preparation of Selenophene-2-carboxylic acid {(S)-2-cyclohexyl-1-[(R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide




- Following the procedure of Example 8 (i-m), except substituting "selenophene-2-carboxylic acid" for "furan-2-carboxylic acid" gave the title compound: ¹H NMR: 8.64(d, 1 H), 8.14(d, 1 H), 7.84(m, 2 H), 7.64(d, 1 H), 7.42(m, 1 H), 7.22(m, 1 H), 6.88(d, 1 H), 6.60(d, 1 H), 5.01(m, 1 H), 4.71(d, 1 H), 4.50(m, 1 H), 4.34(m, 1 H), 3.77(d, 1 H), 2.05(m, 2 H), 1.78-0.82(m, 18 H); Electrospray mass spec: M+H⁺ = 593.2.
- 20

78

60273811.030701

224
218**Example 38**

Preparation of Furan-2-carboxylic acid [(S)-2-cyclohexyl-1-((4S,7R)-7-methyl-3-oxo-1-propyl-azepan-4-ylcarbamoyl)-ethyl]-amide



- 5 a. [(S)-2-Cyclohexyl-1-((3S,4S,7R)-3-hydroxy-7-methyl-1-propyl-azepan-4-ylcarbamoyl)-ethyl]-carbamic acid tert-butyl ester

[(S)-2-Cyclohexyl-1-((3S,4S,7R)-3-hydroxy-7-methyl-azepan-4-ylcarbamoyl)-ethyl]-carbamic acid-tert-butyl ester (Example 1a-I, 1.5 g, 3.78 mmol) was dissolved in CH_2Cl_2 (30 mL), then propionaldehyde (0.41 mL, 5.67 mmol) was added. Then, sodium borohydride (1.6 g, 7.56 mmol) was added and the reaction mixture was stirred at RT for 1 h. The reaction mixture was concentrated *in vacuo* by rotary evaporation, then the filtrate (silica gel, 1-4% MeOH/ CH_2Cl_2) to yield the title compound as a white solid (84%, 1.4 g): Electrospray mass spec: $\text{M}+\text{H}^+ = 440.4$.

- 15 b. (S)-2-Amino-3-cyclohexyl-N-((3S,4S,7R)-3-hydroxy-7-methyl-1-propyl-azepan-4-yl)-propionamide

HCl in dioxane (4.0 M, 15 ml) was added to a stirred solution of [(S)-2-Cyclohexyl-1-((3S,4S,7R)-3-hydroxy-7-methyl-1-propyl-azepan-4-ylcarbamoyl)-ethyl]-carbamic acid tert-butyl ester (1.4 g, 3.0 mmol) in MeOH (5 ml). The reaction mixture was stirred for 2h at RT, then was concentrated *in vacuo* by rotary evaporation and was used in the next reaction without further purification (1.4 g).

c. Furan-2-carboxylic acid [(S)-2-cyclohexyl-1-((3S,4S,7R)-3-hydroxy-7-methyl-1-propyl-azepan-4-ylcarbamoyl)-ethyl]-amide

- 25 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide (0.10 g, 0.53 mmol) was added to a solution of furan-2-carboxylic acid (0.059 g, 0.53 mmol), (S)-2-Amino-3-cyclohexyl-N-((3S,4S,7R)-3-hydroxy-7-methyl-1-propyl-azepan-4-yl)-propionamide (0.15 g, 0.36 mmol), 4-methylmorpholine (0.14 g, 0.16 ml, 1.44 mmol), hydroxybenzotriazole (0.071 g, 0.53 mmol) in DMF (2.0 ml) and was stirred at RT overnight. The reaction mixture was then warmed to RT and was stirred overnight. The reaction mixture was diluted with EtOAc (30 ml), washed with H_2O , brine, dried with magnesium sulfate, filtered, concentrated *in vacuo* by rotary evaporation, and chromatographed (silica gel, 2.5% MeOH/ CH_2Cl_2) to yield the title compound (0.12 g, 76%): Electrospray mass spec: $\text{M}+\text{H}^+ = 434.2$.
- 30

79


60273811.030701

d. Furan-2-carboxylic acid [(S)-2-cyclohexyl-1-((4S,7R)-7-methyl-3-oxo-1-propyl-azepan-4-ylcarbamoyl)-ethyl]-amide

Sulfur trioxide-pyridine complex (0.035 g, 2.2 mmol) was added to a solution of Furan-2-carboxylic acid [(S)-2-cyclohexyl-1-((3S,4S,7R)-3-hydroxy-7-methyl-1-propyl-azepan-4-ylcarbamoyl)-ethyl]-amide (0.19 g, 0.44 mmol) in DMSO (4.0 ml) and triethylamine (0.61 ml, 4.4 mmol) was stirred at RT for 1 h. The reaction mixture was diluted with water, then was extracted with EtOAc. Then, the organic layer was extracted with brine. The combined organics were dried with magnesium sulfate, filtered, concentrated in vacuo, and purified by column chromatography (3% methanol/ methylene chloride) gave the title compound (0.15 mg, 79%): ¹H NMR: 7.44(s, 1 H), 7.11(d, 1 H), 7.04(d, 1 H), 6.92(d, 1 H), 6.49(d, 1 H), 5.29(m, 1 H), 4.69(m, 1 H), 3.40(d, 1 H), 3.08(m, 2 H), 2.51(m, 2 H), 1.88-0.81(m, 29 H); Electrospray mass spec: M+H⁺ = 432.2.

Example 39


15 Preparation of Thiophene-3-carboxylic acid [(S)-2-cyclohexyl-1-((4S,7R)-7-methyl-3-oxo-1-propyl-azepan-4-ylcarbamoyl)-ethyl]-amide



Following the procedure of Example 38 (a-c), except substituting "thiophene-3-carboxylic acid" for "furan-2-carboxylic acid" gave the title compound: ¹H NMR: 7.62(d, 1 H), 7.40(d, 1 H), 7.04(d, 1 H), 6.80(d, 1 H), 6.45(d, 1 H), 5.27(m, 1 H), 4.66(m, 1 H), 3.44(d, 1 H), 3.09(m, 2 H), 2.54(m, 2 H), 1.87-0.87(m, 29 H); Electrospray mass spec: M+H⁺ = 448.4.

Example 40

25 Preparation of Benzofuran-2-carboxylic acid [(S)-2-cyclohexyl-1-((4S,7R)-7-methyl-3-oxo-1-propyl-azepan-4-ylcarbamoyl)-ethyl]-amide




Following the procedure of Example 38 (a-c), except substituting "benzofuran-2-carboxylic acid" for "furan-2-carboxylic acid" gave the title compound: ¹H NMR: 7.98(d, 1 H),

7.45(m, 2 H), 7.27(s, 2 H), 6.90(d, 1 H), 6.50(d, 1 H), 5.28(m, 1 H), 4.67(m, 1 H), 3.40(d, 1 H), 3.06(m, 2 H), 2.56(m, 2 H), 1.88-0.80(m, 29 H); Electrospray mass spec: $M+H^+ = 482.4$.

Example 41


- 5 Preparation of 2,2,4-Trideutero-Puran-2-carboxylic acid ((S)-2-cyclohexyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide



- a. Puran-2-carboxylic acid ((S)-2-cyclohexyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide is dissolved in d_4 -methanol (CD_3OD) and D_2O (10:1), then triethyl amine is added and the reaction mixture is stirred for 3 days. Azeotropic with toluene by concentrating *in vacuo* provides the title compound.

Example 42

- 15 Preparation of Thiophene-3-carboxylic acid ((S)-3,3-dimethyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl)-amide




- Following the procedure of Example 8 (a-m), except substituting "N-Boc-tert-butylalanine" for "Boc-L-cyclohexylalanine" and "thiophene-3-carboxylic acid" for "furan-2-carboxylic acid" gave the title compound: 1H NMR: 8.72(m, 1 H), 7.96(m, 2 H), 7.48(m, 2 H), 7.00(m, 3 H), 6.60(m, 2 H), 5.18(m, 1 H), 4.67(m, 2 H), 4.42(m, 1 H), 3.88(m, 1 H), 2.87(m, 2 H), 2.22(m, 2 H), 1.95(m, 1 H), 1.70(m, 2 H), 1.01(m, 12 H); Electrospray mass spec: $M+H^+ = 521.4$.

221

Example 43

Preparation of Furan-2-carboxylic acid ((S)-3,3-dimethyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl)-amide




- 5 Following the procedure of Example 8 (a-m), except substituting "N-Boc-tert-butylalanine" for "Boc-L-cyclohexylalanine" gave the title compound: ¹H NMR: 8.73(d, 1 H), 7.95(m, 3 H), 7.54(m, 1 H), 7.41(m, 1H), 7.32(m, 1H), 7.26(s, 1 H), 7.01(d, 1 H), 6.56(d, 1 H), 5.08(m, 1 H), 4.73(m, 2 H), 4.43(m, 1 H), 3.88(d, 1 H), 2.18(m, 2 H), 1.70(m, 3 H), 1.04(s, 9 H), 0.98(d, 3 H); Electrospray mass spec: M+H⁺ = 505.4.

10

Example 44

Preparation of Thieno[3,2-b] thiophene-2-carboxylic acid ((S)-3,3-dimethyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl)-amide



- 15 Following the procedure of Example 8 (a-m), except substituting "N-Boc-tert-butylalanine" for "Boc-L-cyclohexylalanine" and "thieno[3,2-b] thiophene-2-carboxylic acid" for "furan-2-carboxylic acid" gave the title compound: ¹H NMR: 8.73(d, 1 H), 7.92(m, 3 H), 7.52(m, 2 H), 7.27(m, 1H), 7.09(br, 1 H), 6.80(br, 1 H), 5.10(m, 1 H), 4.77(m, 2 H), 4.40(m, 1 H), 3.87(d, 1 H), 1.90(m, 5 H), 1.05(s, 9 H), 0.95(d, 3 H); Electrospray mass spec: M+H⁺ = 577.2.
- 20


- The above specification and Examples fully disclose how to make and use the compounds of the present invention. However, the present invention is not limited to the particular embodiments described hereinabove, but includes all modifications thereof within the scope of the following claims. The various references to journals, patents and other publications which are cited herein comprise the state of the art and are incorporated herein by reference as though fully set forth.
- 25

82

60273811-020701


We claim:

1. A method of inhibiting cathepsin S, comprising administering to a patient in need thereof an effective amount of a compound of Formula I:





wherein:

R¹ is selected from the group consisting of:



R² is selected from the group consisting of: H, C₁₋₆alkyl, C₃₋₆cycloalkyl-C(=O)-alkyl, Ar-C(=O)-alkyl, Het-C(=O)-alkyl, R⁹C(O)-, R⁹C(S)-, R⁹SO₂-, R⁹OC(O)-,



R³ is selected from the group consisting of: H, C₁₋₆alkyl, C₃₋₆cycloalkyl-C(=O)-alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, HetC(=O)-alkyl, ArC(=O)-alkyl, Ar-ArC(=O)-alkyl, Ar-HetC(=O)-alkyl, Het-ArC(=O)-alkyl, and Het-HetC(=O)-alkyl;

R³ and R⁴ may be connected to form a pyrrolidine, piperidine or morpholine ring;

R⁴ is selected from the group consisting of: H, C₁₋₆alkyl, C₃₋₆cycloalkyl-C(=O)-alkyl, Ar-C(=O)-alkyl, Het-C(=O)-alkyl, R⁵C(O)-, R⁵C(S)-, R⁵SO₂-, R⁵OC(O)-, R⁵R¹³NC(O)-, and R⁵R¹³NC(S)-;

223

R^5 is selected from the group consisting of: H, C_1 -alkyl, C_2 -alkenyl, C_2 -alkynyl, C_3 -cycloalkyl- C_0 -alkyl, Ar- C_0 -alkyl and Het- C_0 -alkyl;

R^6 is selected from the group consisting of: H, C_1 -alkyl, C_3 -cycloalkyl- C_0 -alkyl, Ar- C_0 -alkyl, and Het- C_0 -alkyl;

5 R^7 is selected from the group consisting of: H, C_1 -alkyl, C_3 -cycloalkyl- C_0 -alkyl, Ar- C_0 -alkyl, Het- C_0 -alkyl, $R^{10}C(O)-$, $R^{10}C(S)-$, $R^{10}SO_2-$, $R^{10}OC(O)-$, $R^{10}R^{14}NC(O)-$, and $R^{10}R^{14}NC(S)-$;

R^8 is selected from the group consisting of: H, C_1 -alkyl, C_2 -alkenyl, C_2 -alkynyl, Het- C_0 -alkyl and Ar- C_0 -alkyl;

10 R^9 is selected from the group consisting of: C_1 -alkyl, C_3 -cycloalkyl- C_0 -alkyl, Ar- C_0 -alkyl and Het- C_0 -alkyl;

R^{10} is selected from the group consisting of: C_1 -alkyl, C_3 -cycloalkyl- C_0 -alkyl, Ar- C_0 -alkyl and Het- C_0 -alkyl;

15 R^{11} is selected from the group consisting of: H, C_1 -alkyl, Ar- C_0 -alkyl, and Het- C_0 -alkyl;

R^{12} is selected from the group consisting of: H, C_1 -alkyl, Ar- C_0 -alkyl, and Het- C_0 -alkyl;

R^{13} is selected from the group consisting of: H, C_1 -alkyl, Ar- C_0 -alkyl, and Het- C_0 -alkyl;

20 R^{14} is selected from the group consisting of: H, C_1 -alkyl, Ar- C_0 -alkyl, and Het- C_0 -alkyl;


R' is selected from the group consisting of: H, C_1 -alkyl, Ar- C_0 -alkyl, and Het- C_0 -alkyl;

25 R'' is selected from the group consisting of: H, C_1 -alkyl, Ar- C_0 -alkyl, or Het- C_0 -alkyl;

R''' is selected from the group consisting of: H, C_1 -alkyl, C_3 -cycloalkyl- C_0 -alkyl, Ar- C_0 -alkyl, and Het- C_0 -alkyl;

X is selected from the group consisting of: CH_2 , S, and O;

30 Z is selected from the group consisting of: $C(O)$ and CH_2 ; and pharmaceutically acceptable salts, hydrates and solvates thereof.



2. A method according to Claim 1 wherein in said compound R^1 is

84

50273841-030701

238
224

3. A method according to Claim 2 wherein in said compound R³ is C₃₋₆cycloalkyl-C₀₋₆alkyl.

4. A method according to Claim 3 wherein in said compound R³ is cyclohexylmethyl.

5. A method according to Claim 2 wherein in said compound R⁴ is R⁵C(O)-.

6. A method according to Claim 5 wherein in said compound R⁵ is selected from the group consisting of: C₁₋₆alkyl, C₃₋₆cycloalkyl-C₀₋₆alkyl, Ar-C₀₋₆alkyl and Het-C₀₋₆alkyl.

7. A method according to Claim 6 wherein in said compound R⁵ is selected from the group consisting of:

furanyl;
benzofuranyl;
thiophenyl;
furo[3,2-b]-pyridine-2-yl;
thiazolyl;
phenyl;
cyclobutyl;
cyclopentyl;
tetrahydrofuranyl;
selenophenyl; and
thieno[3,2-b]thiophenyl.

8. A method according to Claim 6 wherein in said compound R⁵ is selected from the group consisting of:

furanyl and furan-3-yl;
benzofuran-2-yl;
thiophene-3-yl and thiophene-2-yl;
furo[3,2-b]-pyridine-2-yl;
thiazole-5-yl;
tetrahydrofuran-2-yl;
selenophene-2-yl; and
thieno[3,2-b]thiophene-2-yl.

25

60273811.030701

89
225

9. A method according to Claim 6 wherein in said compound R⁵ is selected from the group consisting of:
- aryl substituted furanyl;
 - C₁₋₆alkoxy substituted benzofuranyl;
 - 5 Het-C₀₋₆alkyl-thiophenyl, C₁₋₆alkyl-thiophenyl and C₁₋₆alkoxy-thiophenyl,
 - C₁₋₆alkyl-furo[3,2-b]-pyridine-2-yl,
 - Het-C₀₋₆alkyl-thiazoly); and
 - halogen substituted phenyl.
10. A method according to Claim 6 wherein in said compound R⁵ is selected from the group consisting of:
- 5-(3-trifluoromethyl-phenyl)-furan-2-yl and 5-(4-chloro-phenyl)-furan-2-yl;
 - 5,6-dimethoxy-benzofuran-2-yl and 5-(2-morpholin-4-yl-ethoxy)benzofuran-2-yl;
 - 5-pyridin-2-yl- thiophene-2-yl, 5-methyl-thiophene-2-yl, 3-methyl-thiophene-2-yl;
 - 15 and 3-ethoxy-thiophene-2-yl;
 - 3-methyl-furo[3,2-b]-pyridine-2-yl;
 - 4-methyl-2-pyridin-2-yl-thiazole-5-yl; and
 - 4-bromophenyl.
11. A method according to Claim 1 wherein in said compound R' is H.
12. A method according to Claim 1 wherein in said compound R" is H.
13. A method according to Claim 1 wherein in said compound R^{'''} is selected from the group consisting of: H and C₁₋₆alkyl.
14. A method according to Claim 1 wherein in said compound R^{''} is H and R^{'''} is selected from the group consisting of: H and C₁₋₆alkyl.
15. A method according to Claim 13 wherein in said compound R^{'''} is H.
16. A method according to Claim 13 wherein in said compound R^{'''} is C₁₋₆alkyl.
17. A compound according to Claim 16 wherein C₁₋₆alkyl is selected from the group consisting of: 5-, 6- and 7-C₁₋₆alkyl.

86

0273814.030701

226

18. A compound according to Claim 17 wherein 5-, 6- and 7-C₁₋₆alkyl is selected from the group consisting of: 5-, 6- or 7- methyl, -ethyl, -propyl, -butyl, -pentyl, and -hexyl.

19. A compound according to Claim 21 wherein 5-, 6- and 7-C₁₋₆alkyl is selected from the group consisting of: 5-, 6- and 7-methyl.

20. A compound according to Claim 16 wherein C₁₋₆alkyl is selected from the group consisting of: 6- and 7-C₁₋₆alkyl.

21. A compound according to Claim 20 wherein 6- and 7-C₁₋₆alkyl is selected from the group consisting of: 6- or 7- methyl, -ethyl, -propyl, -butyl, -pentyl, and -hexyl.


22. A compound according to Claim 21 wherein 6- and 7-C₁₋₆alkyl is selected from the group consisting of: 6- and 7-methyl.

23. A compound according to Claim 16 wherein C₁₋₆alkyl is 7-C₁₋₆alkyl.

24. A compound according to Claim 23 wherein 7-C₁₋₆alkyl is selected from the group consisting of: 7- methyl, -ethyl, -propyl, -butyl, -pentyl, and -hexyl.

25. A compound according to Claim 24 wherein 7-C₁₋₆alkyl is 7-methyl.

26. A compound according to Claim 16 of Formula Ia:



Ia

wherein R⁵ is *cis*-7-C₁₋₆alkyl.

27. A compound according to Claim 26 wherein R⁵ is *cis*-7-methyl.

28. A method according to Claim 1 wherein in said compound R² is R⁹SO₂.

85

60273811.030701

227 233


29. A method according to Claim 28 wherein in said compound R^9 is Het-C₀₋₆alkyl.

30. A method according to Claim 29 wherein Het-C₀₋₆alkyl is selected from the group
5 consisting of: pyridinyl and 1-oxy-pyridinyl.

31. A method according to Claim 30 wherein R^9 is pyridin-2-yl.

32. A method according to Claim 1 wherein in said compound:
10

R^1 is



R^2 is $R^9\text{SO}_2$;

R^3 is C₃₋₆cycloalkyl-C₀₋₆alkyl;

15 R^4 is $R^5\text{C}(\text{O})$;

R^5 is Het-C₀₋₆alkyl;

R^9 is Het-C₀₋₆alkyl;

R' is H

R'' is H; and

20 R''' is C₁₋₆alkyl.

33. A method according to Claim 1 wherein in said compound:

R^3 is cyclohexylmethyl;

25 R^5 is selected from the group consisting of: furan-2-yl and thiophene-3-yl;

R^9 is pyridin-2-yl; and


R''' is 7-methyl.

34. A method according to Claim 1 wherein said compound is selected from the group
30 consisting of:


88

60273811-030701

2287*




Benzofuran-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




5

5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




10

5-(4-Chloro-phenyl)-furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




15

5-(4-Chloro-phenyl)-furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxo-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;



20


5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxo-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




89

229 235


5,6-Dimethoxy-benzofuran-2-carboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(1-oxo-pyridine-2-sulfonyl)-azepan-4-ylcarbonyl]-ethyl}-amide; and




5 furan-2-carboxylic acid {(S)-2-cyclohexyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbonyl]-ethyl}-amide;



10 benzofuran-2-carboxylic acid {(S)-2-cyclohexyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbonyl]-ethyl}-amide;



15 thiophene-3-carboxylic acid {(S)-2-cyclohexyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbonyl]-ethyl}-amide;




3-methyl-furo[3,2-b]- pyridine-2-carboxylic acid {(S)-2-cyclohexyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbonyl]-ethyl}-amide;


90

60273811.030704

230




5-(2-morpholin-4-yl-ethoxy)-benzofuran-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




5

4-methyl-2-pyridin-2-yl-thiazole-5-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




10

5-pyridin-2-yl-thiophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;



15

furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




thiophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;


91

60273811-030701


23/37




- 5 thiophene-3-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;



- 10 5-methyl-thiophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;



- 15 3-methyl-thiophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




- 20 3-ethoxy-thiophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;


92

S0273811.030701

232




4-bromo-N-((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-benzamide;




5

cyclobutanecarboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




10

cyclopentanecarboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;



15

(S)-tetrahydro-furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




20


(R)-tetrahydro-furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;

93

60273811-030701




furan-3-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




5

5-pyridin-2-yl-thiophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




10

4-methyl-2-pyridin-2-yl-thiazole-5-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




15

5-(2-morpholin-4-yl-ethoxy)-benzofuran-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




234


furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbonyl]-ethyl)-amide;




5 furan-3-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbonyl]-ethyl)-amide;




10 thiophene-3-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbonyl]-ethyl)-amide;



15 thiophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbonyl]-ethyl)-amide;




20 5-methyl-thiophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbonyl]-ethyl)-amide;



3-methyl-thiophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbonyl]-ethyl)-amide;


95

231-13




3-ethoxy-thiophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;

5




selenophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[(R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




10

furan-2-carboxylic acid [(S)-2-cyclohexyl-1-((4S,7R)-7-methyl-3-oxo-1-propyl-azepan-4-ylcarbamoyl)-ethyl]-amide;

15



thiophene-3-carboxylic acid [(S)-2-cyclohexyl-1-((4S,7R)-7-methyl-3-oxo-1-propyl-azepan-4-ylcarbamoyl)-ethyl]-amide;




20

96

60273811.030701


236 ~~236~~

benzofuran-2-carboxylic acid [(S)-2-cyclohexyl-1-[(4S,7R)-7-methyl-3-oxo-1-propyl-azepan-4-ylcarbonyl]-ethyl]-amide;




5


2,2,4-trideutero-Furan-2-carboxylic acid [(S)-2-cyclohexyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbonyl]-ethyl]-amide;



10 thiophene-3-carboxylic acid [(S)-3,3-dimethyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbonyl]-butyl]-amide;




15 furan-2-carboxylic acid [(S)-3,3-dimethyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbonyl]-butyl]-amide; and



20 thieno[3,2-b]thiophene-2-carboxylic acid [(S)-3,3-dimethyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbonyl]-butyl]-amide.


35. A compound according to Claim 34 selected from the group consisting of:

95

237
243


furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide; and

5



thiophene-3-carboxylic acid ((S)-2-cyclohexyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide.

10 36. A compound according to Claim 35 which is:



furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide.

15

37. A method of treatment and prevention of an autoimmune disease comprising inhibiting overexpression of cathepsin S by administering to a patient in need thereof an effective amount of a compound according to any one of Claims 1 to 36.

20 38. A method according to Claim 37 wherein said disease is selected from the group consisting of : rheumatoid arthritis, multiple sclerosis, juvenile-onset diabetes, systemic lupus erythematosus, discoid lupus erythematosus, pemphigus vulgaris, pemphigoid, Grave's disease, myasthenia gravis, Hashimoto's thyroiditis, scleroderma, dermatomyositis,

98

50273811.030701

238

Addison's disease, pernicious anemia, primary myxoedema, thyrotoxicosis, autoimmune atrophic gastritis, stiff-man syndrome, Goodpasture's syndrome, sympathetic ophthalmia, phacogenic uveitis, autoimmune haemolytic anaemia, idiopathic thrombocytopenic purpura, idiopathic leucopenia, primary biliary cirrhosis, active chronic hepatitis, cryptogenic cirrhosis, ulcerative colitis, Sjogren's syndrome, and mixed connective tissue disease.

39. A method of treatment or prevention of a disease state caused by the formation or complications of atherosclerotic lesions comprising inhibiting formation of said lesions or complications thereof by administering to a patient in need thereof an effective amount of a compound according to any one of Claims 1 to 36.

40. A method of treatment of a disease which requires for therapy inhibition of a class II MHC-restricted immune response, comprising inhibiting said class II MHC-restricted immune response by administering to a patient in need thereof an effective amount of a compound according to any one of Claims 1 to 36.

41. A method of treatment of a disease which requires for therapy inhibition of an asthmatic response, comprising inhibiting said asthmatic response by administering to a patient in need thereof an effective amount of a compound according to any one of Claims 1 to 36.

42. A method of treatment of a disease which requires for therapy inhibition of an allergic response, comprising inhibiting said allergic response by administering to a patient in need thereof an effective amount of a compound according to any one of Claims 1 to 36.

43. A method of treatment of a disease which requires for therapy inhibition of an immune response against a transplanted organ or tissue, comprising inhibiting said immune response against a transplanted organ or tissue by administering to a patient in need thereof an effective amount of a compound according to any one of Claims 1 to 36.

44. A method of treatment of a disease which requires for therapy inhibition of elastase activity in atheroma, comprising inhibiting said elastase activity in atheroma by administering to a patient in need thereof an effective amount of a compound according to any one of Claims 1 to 36.

99

50273811.030701

239

45. Use of a compound according to any one of Claims 1 to 36 in the manufacture of a medicament for use in inhibiting cathepsin S.

5 46. Use of a compound according to any one of Claims 1 to 36 in the manufacture of a medicament for use in treatment and prevention of an autoimmune disease.

10 47. A use according to Claim 46 wherein said disease is selected from the group consisting of: rheumatoid arthritis, multiple sclerosis, juvenile-onset diabetes, systemic lupus erythematosus, discoid lupus erythematosus, pemphigus vulgaris, pemphigoid, Grave's disease, myasthenia gravis, Hashimoto's thyroiditis, scleroderma, dermatomyositis, Addison's disease, pernicious anemia, primary myxoedema, thyrotoxicosis, autoimmune atrophic gastritis, stiff-man syndrome, Goodpasture's syndrome, sympathetic ophthalmia, phacogenic uveitis, autoimmune haemolytic anaemia, idiopathic thrombocytopenic purpura, idiopathic leucopenia, primary biliary cirrhosis, active chronic hepatitis, cryptogenic cirrhosis, ulcerative colitis, Sjogren's syndrome, and mixed connective tissue disease.

20 48. Use of a compound according to any one of Claims 1 to 36 in the manufacture of a medicament for use in treatment or prevention of a disease state caused by the formation or complications of atherosclerotic lesions.

49. Use of a compound according to any one of Claims 1 to 36 in the manufacture of a medicament for use in treatment of a disease which requires for therapy inhibition of a class II MHC-restricted immune response.

25 50. Use of a compound according to any one of Claims 1 to 36 in the manufacture of a medicament for use in inhibition of an asthmatic response.

30 51. Use of a compound according to any one of Claims 1 to 36 in the manufacture of a medicament for use in inhibition of an allergic response.


52. Use of a compound according to any one of Claims 1 to 36 in the manufacture of a medicament for use in inhibition of an immune response against a transplanted organ or tissue.

35 53. Use of a compound according to any one of Claims 1 to 36 in the manufacture of a medicament for use in inhibition of elastase activity in atheroma.


100-

60273811-030701


54. A compound selected from the group consisting of:




5 (pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




10 4-methyl-2-pyridin-2-yl-thiazole-5-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;



15 5-pyridin-2-yl-thiophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;



furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




—



thiophene-3-carboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]carbonyl}-ethyl)-amide;




15




3-ethoxy-thiophene-2-carboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide;

00000000000000000000000000000000

2428




4-bromo-N-((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-benzamide;




5

cyclobutanecarboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




10

cyclopentanecarboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;



15

(S)-tetrahydro-furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




20

(R)-tetrahydro-furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;


103

S0273811-030701

243




furan-3-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




5

5-pyridin-2-yl-thiophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




10

4-methyl-2-pyridin-2-yl-thiazole-5-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;



15

5-(2-morpholin-4-yl-ethoxy)-benzofuran-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;




pdf


50273811-030701

244.5


furan-2-carboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide;



5 furan-3-carboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide;




10 thiophene-3-carboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide;




thiophene-2-carboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide;

15



5-methyl-thiophene-2-carboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide;


20



3-methyl-thiophene-2-carboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide;


25

245




3-ethoxy-thiophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[3-oxo-1-(1-oxo-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide;

5



selenophene-2-carboxylic acid ((S)-2-cyclohexyl-1-[(R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide; and



10

2,2,4-trideutero-Furan-2-carboxylic acid ((S)-2-cyclohexyl-1-[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl)-amide.

5027381.030701

pb

257
246

ABSTRACT OF THE DISCLOSURE

The present invention provides methods which use 4-amino-azepan-3-one protease inhibitors of cathepsin S in the treatment of diseases in which cathepsin S is implicated, especially treatment or prevention of autoimmune disease; treatment or prevention of a disease state caused by the formation of atherosclerotic lesions and complications arising therefrom; and diseases requiring inhibition, for therapy, of a class II MHC-restricted immune response, inhibition of an asthmatic response, inhibition of an allergic response, inhibition of immune response against a transplanted organ or tissue, or inhibition of elastase activity in atheroma, and novel compounds for use therewith.

n:\yps\apps\p51127p1\spec

50273344-030001

107



2do. EXAMEN DE FORMA PATENTE DE INVENCION

Folio-254-

Radicación no 01-20287

Concepto Técnico no 1896

Clasificación Internacional de Patentes: A 61 K 31/55

Practicado el examen de acuerdo a lo establecido en el Art. 38 de la Decisión 486 se determinó que esta solicitud de Patente de Invención:

- SI ☒ NO ☐ Contiene un resumen de la invención (Art.26-e).
- SI ☒ NO ☐ Contiene el título o nombre de la invención (Art.27-d).
- SI ☒ NO ☐ Contiene la descripción de la invención (Art.26-b).
- SI ☒ NO ☐ NO ES APLICABLE ☐ Contiene los dibujos necesarios para comprender la invención (Art.26-d)
- SI ☒ NO ☐ Contiene una o más reivindicaciones. (Art.26-c).
- SI ☐ NO ☐ NO ES APLICABLE ☒ Han sido desarrollados los productos y/o procedimientos a partir de recursos genéticos o de sus productos derivados de los que cualquiera de los Países Miembros es país de origen. (Art. 26- h).
- SI ☐ NO ☐ NO ES APLICABLE ☒ Los productos y/o procedimientos han sido obtenidos o desarrollados a partir de los conocimientos tradicionales de las comunidades indígenas, afroamericanas, o locales de los países miembros, de acuerdo a lo establecido en la Decisión 391 y sus modificaciones y reglamentaciones vigentes.(Art.26-i).
- SI ☐ NO ☒ La invención se refiere a un producto relativo a un material biológico. (Art.26-J).
- SI ☒ NO ☐ La prioridad coincide con la materia reivindicada.
- SI ☒ NO ☐ **CUMPLE LOS REQUISITOS TÉCNICOS**

OBSERVACIONES Y OTROS: SI ☐ NO ☒ ver hoja(s) anexa(s)

EXAMINADOR TÉCNICO
202049

Bogotá D. C., 26 de Diciembre de 2002

Carrera 13 No. 27-00 Piso 5 y 10
Conmutador: 234 12 21-2-3-4
Fax: 281 31 25 e-mail: info@sic.gov.co
Santa Fe de Bogotá D.C. - Colombia



2020
Bogotá DC

Doctor
GERMAN CASTILLO GRAU
Apoderado

REFERENCIA:	Radicación No.	01-29287
	Trámite	002
	Evento	001
	Actuación	416
	Oficio No.	2379
	Folios	001

Teniendo en cuenta que la solicitud de privilegio de patente que se tramita bajo el expediente indicado en la referencia, reúne los requisitos de forma establecidos en los artículos 26 y 27 de la Decisión 486 de la Comisión de la Comunidad Andina, y en las demás disposiciones vigentes sobre la materia, se envía el extracto de la solicitud a la Oficina de Comunicaciones para efecto de su publicación en la Gaceta de Propiedad Industrial, conforme lo establece el artículo 40 de la misma Decisión.

Cúmplase
Dado en Bogotá DC, a los

23 ENE. 2003


CLARA DE JAIMES
Jefe (E) de la División de Nuevas Creaciones

528

202049